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Abstract: Bioactive C17 and C18 acetylenic oxylipins have shown to contribute to the cytotoxic,
anti-inflammatory, and potential anticancer properties of terrestrial plants. These acetylenic oxylipins
are widely distributed in plants belonging to the families Apiaceae, Araliaceae, and Asteraceae,
and have shown to induce cell cycle arrest and/or apoptosis of cancer cells in vitro and to exert
a chemopreventive effect on cancer development in vivo. The triple bond functionality of these
oxylipins transform them into highly alkylating compounds being reactive to proteins and other
biomolecules. This enables them to induce the formation of anti-inflammatory and cytoprotective
phase 2 enzymes via activation of the Keap1–Nrf2 signaling pathway, inhibition of proinflammatory
peptides and proteins, and/or induction of endoplasmic reticulum stress, which, to some extent,
may explain their chemopreventive effects. In addition, these acetylenic oxylipins have shown to
act as ligands for the nuclear receptor PPARγ, which play a central role in growth, differentiation,
and apoptosis of cancer cells. Bioactive C17 and C18 acetylenic oxylipins appear, therefore, to constitute
a group of promising lead compounds for the development of anticancer drugs. In this review,
the cytotoxic, anti-inflammatory and anticancer effects of C17 and C18 acetylenic oxylipins from
terrestrial plants are presented and their possible mechanisms of action and structural requirements
for optimal cytotoxicity are discussed.
Keywords: acetylenic oxylipins; polyacetylenes; cytotoxicity; anti-inflammatory; lead compounds;
mechanisms of action; structure-activity relationship; terrestrial plants
1. Introduction
Polyacetylenes are widely distributed in nature, occurring in terrestrial plants, fungi, bacteria,
mosses, lichens, marine algae, and invertebrates. The majority of polyacetylenes are characterized by a
long hydrocarbon chain consisting of 10 to 42 carbons, and among these, C17 and C18- polyacetylenes
have often been reported to possess potential anticancer effects [1–5]. More than 2500 polyacetylenes
are known, of which the majority have been isolated from terrestrial plants and, in particular,
from the botanically related plant families Apiaceae, Araliaceae, and Asteraceae [1,3]. In plants,
polyacetylenes are biosynthesized from unsaturated fatty acids such as oleic acid and linoleic acid
by dehydrogenation leading to the C18 acetylenic oxylipins crepenynic acid and dehydrocrepenynic
acid. These polyacetylenic precursors are then transformed into C18 acetylenic oxylipins by further
dehydrogenation and oxidation reactions or they may undergo β-oxidation and/or α-oxidation
leading to polyacetylenes of various chain lengths, thus polyacetylenes isolated from terrestrial
plants have typical chain lengths ranging from 10 to 18 carbon atoms [1–3]. Many plants belonging
to particular Apiaceae and Araliaceae families are known for their cytotoxic, anti-inflammatory,
and potential anticancer properties. Although these pharmacological properties have often been
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ascribed to the presence of bioactive terpenoids such as sesquiterpene lactones in Apiaceae and
Asteraceae, and triterpenoid saponins in Araliaceae, there is also strong evidence from numerous
investigations that polyacetylenes constitute a group of highly bioactive compounds in plants of
these families contributing to their pharmacological properties [5–10]. The polyacetylenes in the
Apiaceae and Araliaceae are mainly aliphatic C17 and C18 acetylenic oxylipins, of which acetylenic
oxylipins of the falcarinol-type are the most common, whereas in the Asteraceae a much larger
structural diversity among polyacetylenes is observed, although falcarinol-type oxylipins rarely occur
in this family [1,3,9–12]. However, in some tribes of the Asteraceae such as Anthemideae, Astereae,
and Heliantheae, C17 acetylenic oxylipins of the dehydrofalcarinol-type are common [11–13], and,
like the related falcarinol-type oxylipins, they possess interesting cytotoxic and anti-inflammatory
activities [8].
The triple-bond functionality of acetylenic oxylipins seems to transform these fatty acid derivatives
into highly alkylating compounds that are able to trap thiols or other nucleophiles by direct nucleophilic
addition to their unsaturated electrophilic systems and thus bind covalently to proteins or other
biomolecules with nucleophilic functionalities, as shown in Figure 1 for (3R)-falcarinol [14–16].
Acetylenic oxylipins of the falcarinol-type have, for example, shown to bind covalently to the efflux
protein ABCG2 (also known as the breast cancer resistance protein (BCRP)) involved in breast cancer
chemotherapy resistance [17] as well as to the cannabinoid receptor 1 (CB1) and GABAA receptors
resulting in modulation of the activity of these receptors [15,18]. In addition, this type of acetylenic
oxylipins has also been shown to bind covalently to cysteine in enzymes such as mitochondrial aldehyde
dehydrogenases (ALDHs) in cancer cells leading to a reduction of activity [14]. Reduction of the activity
of ALDHs may lead to oxidative stress and endoplasmic reticulum (ER) stress causing cell injuries, cell
cycle arrest, and apoptosis [19,20], and thus could be one of the mechanisms of action that could explain
the cytotoxicity of falcarinol-type polyacetylenes as well as other acetylenic oxylipins. Furthermore,
acetylenic oxylipins may act as ligands for nuclear receptors such as peroxisome-proliferator-activated
receptors (PPARs). Besides being involved in lipid and glucose metabolism, the PPARs are also involved
in cell proliferation and apoptosis [21,22]. For example PPARγ is involved in glucose metabolism
through the improvement of insulin sensitivity, representing a potential therapeutic target of type 2
diabetes, but is also thought to have overall anticancer effects in many different cancer cell types, due
to its antiproliferative and proapoptotic properties [21,22]. Endogenous ligands for the PPARs are fatty
acids and fatty-acid derivatives and it has, for example, been demonstrated that (3R)-falcarinol (1) and
(3R,8S)-falcarindiol (5) [Figure 2] ligand bind and activate PPARγ [23–25], which may to some extent
explain their potential antidiabetic effects but also their anticancer effects.
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Figure 1. Reaction of (3R)-falcarinol with thiols in proteins or peptides (R–SH) leading to a mixture of
diastereomeric vinyl sulfides of falcarinol. The covalent binding of electrophilic C17 and C18 acetylenic
oxylipins to nucleophilic biomolecules such as proteins/peptides explains to some extent the cytotoxicity
and anti-inflammatory activity of these secondary metabolites.
Molecules 2020, 25, 2568 4 of 42
Figure 2. Cont.
Molecules 2020, 25, 2568 5 of 42
Figure 2. Cont.
Molecules 2020, 25, 2568 6 of 42
Figure 2. Cytotoxic C17 acetylenic oxylipins (1–56) of the falcarinol-type. An asterisk (*) after a
compound number indicates a cytotoxic falcarinol-type polyacetylene of synthetic origin that is not
naturally occurring, but which may prove to be present in plants.
The electrophilic properties of C17 and C18 acetylenic oxylipins and their reaction with thiols in
cysteine indicate that they are able to activate the Kelch-like ECH-associated protein 1 (Keap1)/nuclear
factor erythroid 2–related factor 2 (Nrf2)/antioxidant response element (ARE) pathway. The Keap1-Nrf2
pathway regulates the expression and formation of a battery of antioxidant, anti-inflammatory,
and cytoprotective phase 2 enzymes and therefore this pathway is important in the chemopreventive
protection against carcinogens and inflammation [16,26–30]. Nrf2 is a member of the NF-E2 family
of the basic leucine zipper transcription factors, and is a key transcription factor. Nrf2 regulates the
target genes related to detoxification and antioxidation by binding to ARE. In resting cells, Nrf2 is
bound to Keap1; however, upon exposure to various stimuli, including reactive oxygen species and
electrophilic molecules, Nrf2 is activated and released from the Keap1 complex and translocated
to the nucleus to activate its target genes. The release of Nrf2 from Keap1 may also depend on
phosphorylation of Nrf2, which is mediated through multiple kinases including ERK1/2, PKC, p38,
and PKB (Akt) [28,29]. Carcinogens have been shown to activate the proinflammatory nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) pathway [31]. Consequently, the activation of
the Keap1-Nrf2 pathway by acetylenic oxylipins may contribute significantly to their chemopreventive
effects through detoxification of carcinogens and increased production of anti-inflammatory molecules
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such as carbon monoxide and cytokines that are produced by enzymes such as heme oxygenase-1
(HO-1) [30].
Chronic inflammation is associated with an increased risk of cancer, being linked to approximately
25% of all human cancers [32]. Common causes of chronic inflammation associated with cancer
development include Helicobacter pylori infections in gastric cancer, human papilloma virus in cervical
cancer, hepatitis B or C infections in hepatocellular carcinoma, and inflammatory bowel disease in
colorectal cancer (CRC) [33–35]. The transcription factors NF-κB and signal transducers and activators
of transcription 3 (STAT3) are two major pathways of inflammation that are activated by, for example,
infections that cause chronic inflammation, and thus these transcription factors play a central role in
inflammation-induced cancers [33,35,36]. NF-κB mediate the expression of proinflammatory cytokines,
such as tumor necrosis factor alpha (TNFα), interleukin (IL)-1, and IL6, as well as inflammatory
enzymes, such as cyclooxygenase-2 (COX-2) and 5-lipooxygenase (5-LOX), which are all expressed in
chronic inflamed tissue [33,36]. These proinflammatory stimuli promote carcinogenesis, forming a rich
and complex network of inflammatory responses within the tumor microenvironment contributing to
survival, proliferation, invasion, and metastasis of tumors. COX-2 levels are low in normal tissue but are
rapidly induced as an early response to growth factors, cytokines and tumor promoters associated with
inflammation, cell survival, abnormal proliferation, angiogenesis, invasion, and metastasis [37]. Thus
COX-2 has an important function in driving carcinogenesis and this is done through the production of
prostaglandins (PGs), which inhibit apoptosis and enhance cell migration of cancer cells, and promote
the formation of blood vessels in tumor tissue (neoangiogenesis) [36–38]. COX-2 levels are increased in
many types of tumors in colorectal [39], bladder [40], breast [41], lung [42], pancreas [43], prostate [44],
and head and neck cancer [45], thus inhibition of COX-2 is an important target for anti-inflammatory
drugs in the treatment of many cancers. TNF-α produced during chronic inflammation appears to
enhance tumor development and dissemination as it is a major cytokine in the tumor microenvironment,
being capable of regulating other proinflammatory cytokines and hence is able to influence several of
the hallmarks of cancer, including stimulation of tumor-cell growth, survival, invasion, metastasis,
and neoangiogenesis [46,47]. Drugs that inhibit TNF-α signaling in inflammatory conditions are
therefore of great interest for the treatment of various cancers. IL-6 is another major tumor-promoting
cytokine produced by both malignant and host cells within the tumor microenvironment [48]. Excess
IL-6 production drives carcinogenesis and for some types of cancers high circulating levels of IL-6
indicate a poor prognosis [49,50]. Likewise, overexpression of COX-2 also indicates poor prognosis for
several types of cancer [39,40,51].
Bioactive C17 and C18 acetylenic oxylipins have been shown to inhibit NF-κB and the formation of
proinflammatory cytokines and inflammatory enzymes such as ILs, COXs and LOXs and, therefore,
the direct inhibition of these inflammatory mediators appears to be another important mechanism of
action for the prevention and treatment of cancer by these secondary metabolites. This has recently
been demonstrated for (3R)-falcarinol and (3R,8S)-falcarindiol isolated from carrots in a rat model
of CRC, where it was shown that these polyacetylenes selectively inhibited the expression of COX-2
in tumor tissue as well as TNF-α and IL-6, thus explaining the CRC preventive effect of carrots
and related root vegetables [52,53]. This will be discussed in more details in Section 4.1. Although,
no pharmacokinetic study in tumors and plasma in this rat study was performed, the lipophilic nature
of these acetylenic oxylipins clearly indicate that they are absorbed in cells affecting tumor growth. This
assumption is supported by a pharmacokinetic study of (3S,8S)-falcarindiol (10) and oplopandiol (18)
in rats after oral administration of a polyacetylene extract of Oplopanax elatus Nakai demonstrating that
these polyacetylenes were rapidly absorbed in vivo [54]. This is also in accordance with a human trial
demonstrating that (3R)-falcarinol and (3R,8S)-falcarindiol is rapidly absorbed in humans after oral
administration of carrot juice containing these polyacetylenes [9,55,56]. The preliminary bioavailability
studies clearly show that C17 and C18 acetylenic oxylipins are bioavailable. This is important in relation
to the interpretation of their cytotoxicity and anti-inflammatory activity in vitro to a chemopreventive
effect in vivo, because bioavailability is a prerequisite for the latter, although in vitro experiments may
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not be able to predict accurately, the effects of these polyacetylenes in vivo. The anticancer effect of
acetylenic oxylipins have only been investigated in a few animal studies as discussed in Section 4, thus
the potential chemopreventive effect of these secondary metabolites are, with a few exceptions, based
on in vitro studies.
The electrophilic nature of C17 and C18 acetylenic oxylipins appears to play a central role
for their cytotoxic, anti-inflammatory and chemopreventive activities. Furthermore, the structural
similarities of these acetylenic oxylipins to endogenous ligands of PPARs and their ability to activate
these nuclear receptors may also contribute to their anticancer effect. Therefore, these secondary
metabolites seem to constitute a group of promising lead compounds for the development of anticancer
drugs for the prevention and possibly treatment of cancers. In this review, the cytotoxicity and
anti-inflammatory activity in vitro of C17 and C18 acetylenic oxylipins isolated from terrestrial plants,
including some synthetic enantiomers of naturally occurring acetylenic oxylipins are presented, as well
as investigations of their in vivo anticancer effects. Furthermore, possible mechanisms of action and
structural requirements for optimal cytotoxicity of these acetylenic oxylipins are discussed.
2. In Vitro Cytotoxicity of C17 and C18 Acetylenic Oxylipins and Structure Activity-Relationship
2.1. Cytotoxic C17 and C18 Acetylenic Oxylipins Isolated from Plants of the Araliaceae
2.1.1. Cytotoxic C17 and C18 Acetylenic Oxylipins from Panax Species
Many plants of the genus Panax (Araliaceae) have been used in traditional medicine in Asia and
in North America against various types of illnesses and diseases. Panax ginseng C.A. Meyer is the
most famous of the Panax species and is also known as Korean ginseng or Asian ginseng. The roots of
P. ginseng have been used as an herbal remedy in eastern Asia for more than 2000 years and is known
for its possible chemopreventive effects [57–59]. The chemopreventive effects of Panax species have
mainly been associated with the content of triterpenoid saponins (ginsenosides) [60] until the discovery
of the potential anticancer activity of the petroleum ether extract from P. ginseng roots around 1980
demonstrating cytotoxic effects to murine leukemia and sarcoma cells [61]. Since then, the lipophilic
part of this plant and other Panax species such as P. quinquefolius L. (American ginseng), P. notoginseng
(Burkill) F.H. Chen (Chinese ginseng) and P. stipuleanatus Tsai and Feng have been investigated for
cytotoxic compounds. This had led to the characterization of several cytotoxic acetylenic oxylipins
of the falcarinol-type (1, 2, 20–22, 29, 31, 32, 34–38, 41–43, 50, 52, 53, Figure 2), panaxydiol-type (57,
58, 60, 63, 68, 69, Figure 3), and dehydrofalcarinol-type (77, 78, 80, 81, Figure 4) as well as the related
acetylenic ginsenoyne J (95) and ginsenoyne I (96) (Figure 5).
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Figure 3. Cytotoxic C17 acetylenic oxylipins (57–71) of the panaxydiol-type. An asterisk (*) after a
compound number, indicates a cytotoxic panaxydiol-type polyacetylene of synthetic origin that is not
naturally occurring, but which may prove to be present in plants.
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Figure 4. Cont.
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Figure 4. Cytotoxic C17 acetylenic oxylipins (72–92) of the dehydrofalcarindiol-type. An asterisk (*)
after a compound number, indicates a cytotoxic dehydrofalcarindiol-type polyacetylene of synthetic
origin that is not naturally occurring, but which may prove to be present in plants.
Figure 5. Miscellaneous cytotoxic C17 and C18 acetylenic oxylipins (93–104) isolated from medicinal
plants belonging to the Araliaceae or Apiaceae families.
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The first interesting studies on the cytotoxic activity of P. ginseng polyacetylenes appeared
between 1987–1990. These early studies demonstrated that panaxydol (20), 1-chloropanaxydiol (35),
dihydropanaxacol (52), and panaxacol (53) [Figure 2], isolated from dried callus, were cytotoxic against
murine leukemia L1210 cells and Yoshida sarcoma cells, resulting in a strong inhibition of the growth
of the cells at 10 µg/mL [62–64]. Furthermore, the cytotoxic activity of falcarinol (1), panaxydol (20),
and panaxytriol (41) (Figure 2) isolated from red P. ginseng roots were found to be highly cytotoxic
against human and murine malignant cells showing the strongest cytotoxic activity towards human
gastric adenocarcinoma (MK-1) cancer cells with an ED50 (median effective dose) of 0.027, 0.016,
and 0.171 µg/mL, respectively, but interestingly relatively low cytotoxicity to human nonmalignant cell
lines [65–67]. Other C17 acetylenic oxylipins (2, 22, 29, 38, 42, 43, 58, 77, 78, 80, 81, 95, 96, Figures 2–5)
isolated from P. ginseng roots have since been tested for their cytotoxic activities against varies human
malignant and murine malignant cells [68,69]. In one study falcarinol, panaxydol, and panaxytriol
showed potent cytotoxicity against the murine malignant cells DT, 3T3, and L1210 that were comparable
with the chemotherapy drugs 5-fluorouracil and cisplatin used as positive controls [68]. The most
potent of the tested acetylenic oxylipins in this study was, however, ginsenoyne A (77), which was
even more potent towards the human malignant cell lines HeLa, T24, and MCF-7 compared to the
positive controls [68]. In another study the acetylenic oxylipins 1, 20, 41, 42, 77, and 81 were tested
for their cytotoxicity against the human cancer cell lines A549, SK-OV-3, SK-MEL-2, and HCT-15 and
falcarinol and ginsenoyne A were the most potent, with ED50 values of 2.38–6.04 µM and 2.14–5.95 µM,
respectively [69]. Most investigations on the cytotoxicity and mechanisms of action of polyacetylenes
isolated from P. ginseng have, however, been performed on panaxydol and panaxytriol.
The inhibitory effects of panaxydol, isolated from P. ginseng, on carcinogenesis and tumor
growth have been demonstrated in numerous investigations on different types of cancer cells [70–76].
The possible mechanisms of action for the antiproliferative effects of this acetylenic oxylipin appears
to involve induction of G1 phase cell cycle arrest and/or apoptosis of cancer cells. Panaxydol has
been shown to inhibit the growth of SK-MEL-1 cells, a human malignant melanoma cell line, and to
induce cell cycle arrest at G1 phase in a dose-dependent manner (0–20 µg/mL), with significant effects
at 10 µg/mL. The induction of G1 phase cell cycle arrest by panaxydol in this study was shown to be
associated by decreasing cyclin-dependent kinase 2 and upregulation of the cyclin-dependent inhibitor
p27kip1 [71]. Induction of cell cycle arrest at G1 to S transition in a dose-dependent manner have also
been demonstrated in the human hepatocarcinoma cell line HepG2 with significant effect already
at 4 µM [72]. The antiproliferative effects of panaxydol of HepG2 cells was shown to be dose- and
time-dependent with IC50 (half maximal inhibitory concentration) values of 12.9, 8.2, and 6.3 µM at
24, 48, and 72 h, respectively. Furthermore, it was demonstrated that panaxydol upregulated the
cyclin-dependent inhibitor p21Waf1/Cip1 and downregulated inhibitors of differentiation/DNA binding
proteins Id-1 and Id-2 that are involved in the cell cycle regulatory system, which may explain the
observed induction of cell cycle arrest of HepG2 cells [72]. Panaxydol has also been shown to induce
cell cycle arrest at G1 phase in non-small-cell lung cancer cells (A549 and NCI-H358), and, like in
SK-MEL-1 cells, the cell cycle arrest was accompanied by a downregulation of cyclin-dependent
kinases and an upregulation of p27kip1 as well as an upregulation of p21Waf1/Cip1 [73]. In addition,
a downregulation of cyclins (D and E) was observed. Cyclins are proteins that control the progression
of a cell through the cell cycle by activating cyclin-dependent kinases. Finally, panaxydol was shown
to induce accumulation of intracellular Ca2+ in non-small-cell lung cancer cells, and this upregulation
of Ca2+ was found to be closely related to the effect on G1 cell cycle arrest [73]. Panaxydol has also
been shown to suppress cell proliferation in rat C6 glioma cells by induction of p27kip1 [74]. Thus,
panaxydol may represent a promising lead compound for the development of drugs for the treatment
of lung cancer and other cancers. Moreover, panaxydol has also shown to induce apoptosis in human
leukemia T cell line (Jurkat), and in a human breast cancer cell line (MCF-7) in concentrations of 40
and 50 µg/mL, respectively. This apoptotic effect was also associated with a rapid increase in the
cytoplasmic Ca2+ concentration activating NADPH oxidase via p38/JNK resulting in the induction of
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oxidative stress and activation of mitochondria-dependent apoptosis [75]. In another study, it was
demonstrated that panaxydol induces apoptosis in MCF-7 cells by activating the epidermal growth
factor receptor (EGFR) and phospholipase Cγ (PLCγ) at 50 µg/mL, although a lower concentration of
panaxydol (20 µg/mL) induced the same signaling events but with slower kinetics [76]. Activation of
EGFR and PLCγ is usually associated with tumor cell migration and tumor growth in many types
of cancer, but, in this study, it was accompanied with Ca2+ release from ER and eventually in an
increased mitochondrial Ca2+ concentration resulting in oxidative stress and ER stress leading to the
observed apoptosis [76]. In addition, combined treatment with panaxydol and the anticancer drug
cisplatin exhibited a synergistic cytotoxic effect in vitro. Cisplatin is known to induce oxidative stress,
suggesting the possibility of combination therapy. Based on the current studies on the antiproliferative
effects of panaxydol, it appears that cell cycle arrest by activating p21Waf1/Cip1 and p27kip1, and ER
stress are the main mechanisms of action. ER stress can lead to apoptosis but may also result in cell
cycle arrest by activating the tumor suppressor protein p53 [77,78], which also operates by inducing
the expression of p21Waf1/Cip1 [78,79].
Panaxytriol has, in addition to the cytotoxicity described above, shown to inhibit mitochondrial
respiration of a human breast carcinoma cell line (M25-SF) [80] and to enhance the cytotoxic activity
of the chemotherapeutic agent mitomycin C against the human gastric carcinoma cell line, MK-1,
in a synergistic manner [81]. Moreover, studies on the inhibitory effects of carcinogenesis and
tumor growth of panaxytriol in vivo, as will be discussed in Section 4.2, and in vitro as well
as its possible mechanisms of action have been investigated. In the study by Kim et al. [82],
the cytotoxicity of panaxytriol towards a number of murine and human cancer cell lines was
investigated, including P388D1 (mouse lymphoma), Jurkat (human lymphoma), U937 (human
lymphoma), K562 (human leukemia), NIH/3T3 (mouse fibroblast), SNU-1 (human gastric carcinoma),
SNU-C2A (human colon cancer), PC3 (human prostate cancer), and MCF-7 (human breast cancer), with
IC50 values of 3.1, 11.1, 9.8, 10.8, 7.0, 29.7, 8.3, 19.1, and > 40 µg/mL, respectively, measured through
MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Paclitaxel (taxol) was used
as a positive control with IC50 values ranging from 2.0 to > 40 µg/mL. The study furthermore showed
that the DNA synthesis was strongly inhibited in the tumor cells tested and for two of the most sensitive
cancer lines, P388D1 and SNU-C2A, this inhibitory effect of DNA synthesis was dose-dependent. IC50
values for DNA synthesis inhibition were 0.7 and 7.8 µg/mL for P388D1 and SNU-C2A, respectively.
In addition, panaxytriol was shown to induce cell cycle arrest of P388D1 cells at the G2/M phase, where
the proportion of cells in the G2/M phase of the cell cycle increased from 9% (untreated cells) to 26%
and 48% after 24 and 36 h exposure to 5 µg/mL, respectively. Thus, panaxytriol appears to have both a
dose- and time-dependent inhibitory effect on cell proliferation and that a likely mechanism of action
is induction of cell cycle arrest [82].
The polyacetylenic profile of the roots of P. quinquefolius is very similar to that of P. ginseng,
although P. quinquefolius contain other cytotoxic polyacetylenes that have so far not been found in
P. ginseng. Cytotoxic polyacetylenes that have been isolated from the roots of P. quiquefolius include,
besides falcarinol (1), panaxydol (20) and panaxytriol (41), also the acetylenic oxylipins 21, 29, 31, 32,
34, 36, 37, 42, 50, 57, and 63 (Figures 2 and 3). These polyacetylenes have, so far, only been tested
against murine leukemia L1210 cells where they have shown strong inhibitory activity with IC50 values
of 0.1–1 µg/mL [83–86]. It is, however, interesting that the cytotoxic activity of C17-polyacetylenes
against L1210 cells is approximately 20 times stronger than the corresponding C14-polyacetylenes
with a terminal diyne moiety. This indicates that a terminal double bond in combination with a
secondary allylic alcohol or ester group or ketone at C-3 is important for the cytotoxicity of these
C17-polyacetylenes and/or simply that the chain length is important for the activity as demonstrated for
synthetic symmetric aliphatic diacetylenes, where the cytotoxicity drops off dramatically as the chain
length shortens [87]. Furthermore, the stereochemistry of C17-polyacetylenes from P. quinquefolius
is important for their cytotoxicity as shown in a study by Satoh et al. [83], who investigated the
cytotoxicity of (3R,9R,10S)-panaxydol (20), (3R,9R,10S)-acetylpanaxydol (21), (9R,10S)-ginsenoyne E
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(29), (3R,9R,10R)-panaxytriol (41), (3R,9R,10R)-panaquinquecol 1 (42), (9R,10R)-3-oxo-panaquinquecol
1 (50), and (3R,10S)-panaxydiol (57) against L1210 cells as well as their synthesized optical isomers
(23–28, 30, 44–49, 51, 59–61) [Figures 2 and 3], of which a few also occur naturally in plants of the
Araliaceae family. In this study it was demonstrated that the (3S)-isomers of panaxydol (23, 27),
acetylpanaxydol (24, 28), panaxytriol (44, 48), panaquinquecol 1 (45, 49), and panaxydiol (59, 61)
were approximately 10 times more potent with IC50 values of 0.01–0.1 µg/mL compared to those
with (3R)-configuration (20, 21, 25, 26, 41, 42, 46, 47, 57, 60) with IC50 values of 0.01–0.1 µg/mL [83].
The epoxide group in panaxydol, acetylpanaxydol, and 3-oxo-panaquinquecol 1 is, like the diyne
functionality, susceptible to nucleophilic attack, and, therefore, this functional group is expected to
have some effect on the cytotoxic activity of these compounds. However, no difference in activity
between the (9R,10S)- and (9S,10R)-isomers was observed, which indicates that the epoxide group does
not enhance cytotoxicity significantly compared to the corresponding dioxygenated polyacetylenes
and that the stereochemistry at C-9 and C-10 is of less importance for the activity of C17 acetylenic
oxylipins. Furthermore, the 3-oxo-acetylenic oxylipins, i.e., 29, 30, 50, and 51 showed almost the same
inhibitory activities as the corresponding (3R)-isomers (20, 25, 42, 47). The above results indicate that
the diyne functionality and the stereochemistry at C-3 are most important for the cytotoxic activity of
C17 acetylenic oxylipins isolated from P. quinquefolius.
Panax notoginseng has not been studied as thoroughly for its content of cytotoxic polyacetylenes as
P. ginseng and P. quinquefolius. However, the major polyacetylenes in P. notoginseng are the same, i.e.,
falcarinol (1), panaxydol and panaxydiol [88,89]. Falcarinol and panaxydol isolated from P. notoginseng
have been investigated for their inhibitory effects on cell growth of human acute promyelocytic
leukemia (HL-60) cells. It was found that they markedly inhibited proliferation of HL-60 cells in a
time- and dose-dependent manner via an apoptotic pathway associated with proteolytic cleavage
of the protein kinase C delta type (PKCδ), caspase-3 activation and degradation of poly ADP ribose
polymerase (PARP) [89].
Panax stipuleanatus is a traditional herb that grows mainly in the north of Vietnam and the roots
have been used in traditional medicine for the treatment of bleeding and muscular pain. Recent
research has also indicated that this herb has anticancer and anti-inflammatory activities [90]. Chemical
investigations of the roots of P. stipuleanatus resulted in the isolation of the cytotoxic panaxydiol-type
polyacetylenes 60, 68 and 69 (absolute configuration at C-3 and C-10 in this case unknown) [Figure 3]
as well as panaxytriol (41) [90,91]. Among them, (3R,10R)-panaxydiol (60) and stipuol (68) showed
significant cytotoxic activity, with IC50 values of 0.13 and 0.28 µM, respectively, against HL-60 cells,
and 0.50 and 0.80 µM, respectively, against human colon cancer (HCT-116) cells. Investigation of the
mechanisms of action of these polyacetylenes indicated that they markedly inhibited the proliferation
of HL-60 and HCT-116 cells by induction of apoptosis [90].
2.1.2. Cytotoxic C17 and C18 Acetylenic Oxylipins from Other Plant Species of the Araliaceae
Other medicinal plants of the Araliaceae family that have resulted in the isolation of cytotoxic
acetylenic oxylipins include species from the genera Aralia, Dendropanax, Hedera, Oplopanax,
and Schefflera. Oplopanax horridus (Araliaceae), known as Devil’s Club, is probably the most important
ethnobotanical to indigenous people living in the Pacific northwest of North America, and, except
for some Panax species, it is perhaps one of the most studied medicinal plants of the Araliaceae
family. The traditional medicine uses the stem or root bark of O. horridus in treatment of external
and internal infections and illnesses such as arthritis, respiratory ailments, digestive tract ailments,
and fever [6,92–94]. In addition, it has been described that indigenous people in North America
have used infusions of the bark of O. horridus as a possible treatment of cancer, although no solid
documentation of its traditional use in cancer treatment exits [6]. However, recent pharmacological
research has shown that the hydrophobic parts of ethanol extracts of root bark extracts of O. horridus
inhibit the proliferation of several breast, colorectal, lung, ovarian, and acute myeloid leukemia
cancer cell lines as well as cancer cells in animal models [6,94–100]. Investigations of O. horridus
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extracts, in particular in colon cancer cell lines, have shown that the mechanisms of action for
the anticancer effect of the extracts is most likely caused by induction of apoptosis and arrest
of the cell cycle at the G2/M phase [6,94,95,97,99]. The bioactive constituents responsible for the
possible anticancer effect of O. horridus extracts appears mainly to be due to the C17 and C18
acetylenic oxylipins (3S)-falcarinol (3), (3S,8S)-falcarindiol (10), oplopandiol (18), oplopantriol A
(97), (9Z,11S,16S)-11,16-dihydroxyoctadeca-9,17-dien-12,14-diyn-1-yl acetate (98), oplopantriol B (100),
and oplopandiol acetate (101) [Figures 2 and 5]. These polyacetylenes have all been isolated from
root and/or stem bark extracts of O. horridus [6,93–95,101–106]. Investigations of the antiproliferative
effects of the polyacetylenes from O. horridus have mainly been performed on human breast cancer
(MCF-7, MDA-MB-231), human colon cancer (HCT-116, HT-29, SW-480), human liver cancer (HepG2),
human pancreatic cancer (PANC-1, Bx-PC3) and human lung adenocarcinoma epithelial (A549) cell
lines [6,94,102–107]. Based on these in vitro studies, it appears that (3S,8S)-falcarindiol (10) and
oplopantriol A (97) show the strongest antiproliferative effects, in particular towards colon cancer
cell lines, where they have been shown to significantly inhibit the cell growth of HCT-116, HT-29,
and SW-480 cell lines at or below 10 µM. Their mechanisms of action appear to be cell cycle arrest
in the G2/M phase and inhibition of proliferation by the induction of apoptosis at both earlier and
later stages; thus contributing to an explanation for the observed anticancer activity of O. horridus
extracts [94,102,103]. In the case of oplopantriol A, it has furthermore been demonstrated that this
cytotoxic compound suppresses growth of HCT-116 and SW-480 cells both in a concentration- and
time-dependent manner, with IC50 values of approximately 5 µM for HCT-116 and 7 µM for SW-480
cells [103]. Moreover, it has been shown that oplopantriol A inhibits cell proliferation and induces
cell death in breast cancer (MDA-MB-231), mouse leukemia (MLL-AF9), HCT-116 as well as in
lymphoblastic leukemia (KOPN1) cells but not in nontumorigenic cells, indicating that oplopantriol A
preferentially is cytotoxic towards cancer cells [106]. The mechanisms of action by which oplopantriol
A induces cell death in these cancer cells has been shown to be through induction of endoplasmic
reticulum (ER) stress and the apoptotic BH3 proteins Noxa and Bim [106]. More or less the same effects
have been observed for falcarindiol (10) on HCT-116 and SW-480 cells where it has been demonstrated
that falcarindiol preferentially induced cell death and apoptosis of cancer cells but not normal colon
epithelial cells and that its antiproliferative effect was mediated by induction of ER stress and activation
of the unfolded protein response (UPR) [107]. Furthermore, the antitumor effects of falcarindiol and
oplopantriol A have been demonstrated in xenograft tumor models in mice, as discussed in Section 4.2.
Thus, ER stress and, thereby, induction of apoptosis and cell cycle arrest could be an important
mechanism of action for the cytotoxicity of these acetylenic oxylipins in cancer cells.
A study on the cytotoxic effect of synthetic falcarinol (mixture of isomers), falcarindiol 3-acetate
(8, mixture of isomers), and dihydrofalcarindiol (17), as well as the C18 derivative of oplopantriol A
(98), isolated from O. horridus, against human pancreatic ductal adenocarcinoma cell lines PANC-1
and BxPC-3 showed that synthetic falcarinol, falcarindiol 3-acetate, and the C18 polyacetylene 98
were potent inhibitors of proliferation with IC50 values of < 1 µg/mL. In comparison, the synthetic
dihydrofalcarinol gave IC50 values of > 10 mg/mL when tested against PANC-1 and Bx-PC3 cells [108].
Studies on the mechanisms of action of falcarinol and the C18 polyacetylene 98 showed that both
compounds modulated genes related to proapoptosis, antiapoptosis, apoptosis, cell cycle, stress,
and death receptors and is more or less in accordance with the mechanisms of action of these
compounds on other types of cancer cells [108]. This study indicates that C17 and C18 acetylenic
oxylipins with a terminal double bond are potent inhibitors of pancreatic cancer cell proliferation
compared to corresponding polyacetylenes with a terminal single bond. However, from a study on
the cytotoxicity of two falcarinol-type polyacetylenes, oploxyne A (39) and oploxyne B (54), with
a terminal single bond and isolated from the related Oplopanax elatus [109,110], it is clear that the
cytotoxicity also depends on the cancer cell lines. The screening of oploxyne A and B and a synthetic
epimer of oploxyne A (40) for cytotoxicity against the cancer cell lines A549 (lung cancer), MCF-7
(breast), DU-145 (prostate), and SK-N-SH (neuro-blastoma), measured through a MTT assay, showed
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that oploxyne A (IC50 value of 7 µM) and its C-10 epimer (40) (IC50 value of 12 µM) were better than or
similar to the positive control doxorubicin (IC50 value of 9 µM) against the human neuroblastoma cell
line. Oploxyne B, on the other hand, was effective against DU-145 cells with an IC50 value of 17 µM
but less effective than doxorubicin (IC50 value of 11 µM). However, against the other cancer cell lines,
oploxyne A and its epimer showed moderate or no cytotoxic effect (IC50 > 27 µM) and the same is true
for oploxyne B (IC50 > 30 µM) [110].
Based on a structure–activity relationship analysis of the cytotoxic activity of C17 and C18 acetylenic
oxylipins, isolated from O. horridus, and synthetic derivatives, it appears that a terminal double bond
(vinyl group) is important for their cytotoxicity as they seem to be much more cytotoxic than their
corresponding dihydro derivatives, i.e., 17, 18, 100 and 101 [6,94,102,104,108]. This observation could
indicate that this type of terminal double bond makes polyacetylenes more reactive and/or easier to
transform into other metabolites in vivo. This may result in an induction of phase II enzymes and
other cytoprotective enzymes such as NAD(P)H: quinone: oxidoreductase (NQO-1) and HO-1 as
demonstrated for falcarindiol isolated from different Apiaceae plants [16,27,111]. This assumption is
supported by data from the pharmacokinetic study of falcarindiol (10) and oplopandiol (18) in rats,
which showed that the elimination half-life (T1/2) value of 18 was approximately 10 times higher than
that of 10, indicating a much higher metabolization rate in vivo of polyacetylenes with a terminal
double bond compared to their dihydro derivatives [54]. Therefore, not only does the diyne system of
C17 and C18 acetylenic oxylipins seem to play a role for the activation of the Keap1-Nrf2 pathway but
so does the presence of a terminal double bond in the vicinity to the butadiynylcarbinol moiety of these
acetylenic oxylipins. However, further studies are needed to explore the relationship and importance
of such a terminal double bond with the activation of the Keap1-Nrf2 pathway and anticancer effect of
C17 and C18 polyacetylenes. In addition, it has been shown that the cytotoxicity of synthetic acetylated
derivatives of the polyacetylenes isolated from O. horridus become weaker if their hydroxyl groups are
acetylated or they contain one more methylene group in the main skeleton chain, i.e., C17 polyacetylenes
are, in general, more cytotoxic than the C18 polyacetylenes [104]. The cytotoxicity of the synthetic
derivatives of O. horridus polyacetylenes are not included due to poor activity but a full description
of their cytotoxicity can be found in reference [104]. Thus, the hydroxyl groups and the chain length
of O. horridus polyacetylenes also appears to have some effect on their potential anticancer activity,
and, furthermore, a terminal allylic secondary alcohol moiety contributes to the enhancement of the
anticancer activity of C17 and C18 acetylenic oxylipins.
That a terminal double bond may be important for the cytotoxicity of C17 and C18 acetylenic
oxylipins has been confirmed in a study on the cytotoxicity of falcarinol-type (3, 10), panaxydiol-type
(59 or 61, 67) and dehydrofalcarinol-type (72, 73) oxylipins isolated from Dendropanax arboreus (L.)
Decne. & Planch. (Araliaceae) against the human disease-oriented tumor cell line screening panel
(National Cancer Institute, USA) consisting of 60 human tumor cell lines (NCI-60 human tumor cell
panel) [112]. The patterns of differential cytotoxicity for the isolated polyacetylenes from D. arboreous
were virtually superimposable, although small differences in potency were observed through the
series. Inclusion of a vinyl group in position 16,17 led to a slight reduction in potency from 3→ 72,
10→ 73, and 59/61→ 67. The lowest cytotoxic potency was observed for dendroarboreol A (79), which
is probably due to saturation of the vinyl group in position 1,2, in accordance with the structure-activity
analysis of cytotoxic polyacetylenes isolated from O. horridus.
From Japanese ivy (Hedera rhombea Siebold and Zucc. ex Bean), an indole derivative of falcarindiol
(11) has been isolated from the flower buds, which has shown interesting antiproliferative effects in
the human promyelocytic leukemia HL-60 cell line [113,114]. This polyacetylene inhibited the HL-60
cell growth at 0.1 and 1.0 µg/mL, whereas it was cytotoxic at 10 µg/mL. The growth suppression
induced by 11 was accompanied by G0/G1 phase arrest in the cell cycle at 1.0 µg/mL and, interestingly,
induced the granulocytic differentiation of HL-60 cells. A common goal of cancer therapy is to restore
normal growth of transformed cells, and therefore this falcarindiol derivative could act as a potential
chemotherapeutic agent in human leukemia therapy.
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Cytotoxic C17 and C18 acetylenic oxylipins in the Araliaceae, besides the above-mentioned plant
species, have also been found in the roots of Acanthopanax senticocus (Rupr. et Maxim) Harms (20, 33,
63) where they seem to induce various proapoptosis mechanisms in animal cells [8]. From the leaves
of Schefflera taiwaniana (Nakai) Kaneh., falcarindiol (10) and the related C18 polyacetylene 98 have been
isolated showing inhibition of human nasopharyngeal carcinoma (HONE-1) and human gastric cancer
(NUGC) cell lines at 50 µg/mL [115].
2.2. Cytotoxic C17 and C18 Acetylenic Oxylipins Isolated from Plants of the Asteraceae
Acetylenic oxylipins are characteristic for the Asteraceae and the large structural variation among
this type of secondary metabolites in this family makes them appropriate chemotaxonomic markers.
The chemical structures of these polyacetylenes also indicates that they are bioactive compounds with
potential anticancer effects. Although investigations on the cytotoxicity of polyacetylenes isolated
from Asteraceae are limited, it has been demonstrated that different types of polyacetylenes from this
family possess cytotoxic activity including C13 and C14 spiro ethers, aromatic and aliphatic C10 and C11
polyacetylenes as well as C17 polyacetylenes of the dehydrofalcarinol-type [3,5,8]. Dehydrofalcarinol
and its derivatives are common in certain tribes of the Asteraceae, but their potential anticancer effects
have only been investigated in a few studies.
From an aqueous ethanol extract of the roots of Gymnaster koraiensis (Nakai) Kitamura, several
cytotoxic polyacetylenes of the dehydrofalcarinol-type were isolated (73, 75, 76, 82, 83, 85, 86) by
bioassay-guided fractionation using the murine leukemia L1210 tumor cell line as a model for
cytotoxicity [116]. The chemical structure of gymnasterkoreayne E (83) in this study was later
revised after the isolation of gymnasterkoreayne G (84) from G. koraiensis [117]. Of the cytotoxic
C17-polyacetylenes from G. koraiensis, (3S,8S)-dehydrofalcarindiol (73) and gymnasterkoreayne C (75)
exhibited significant cytotoxicity against the L1210 tumor cells, with ED50 values of 2.1 and 0.12 µg/mL,
respectively, while compounds 76, 82, 83, 85 and 86 were less potently cytotoxic with ED50 values
of 3.1–10.4 µg/mL [116]. These cytotoxic polyacetylenes also occur in the flowers of the plant [118].
The above results indicates that a terminal double bond (vinyl group) in the vicinity to the diyne moiety
is important for the enhancement of the cytotoxicity of G. koraiensis polyacetylenes against L1210 tumor
cells, and confirm the results from the structure-activity analysis of other cytotoxic C17 acetylenic
oxylipins described in Section 2.1. In addition, the cytotoxicity of (8S)-gymnasterkoreayne F (85) and
its synthetic (8R)-isomer (87) have been evaluated over a five-log dose range in the NCI-60 human
tumor cell panel exhibiting modest cytotoxicity with full-panel mean-graph midpoint (MG–MID) Log
GI50 values of –4.44 (85) and –4.27 (87), respectively [119]. Nevertheless, gymnasterkoreayne F (85)
had a Log GI50 value of –5.44 against the HL-60 leukemia cell line, whereas 87 had a Log GI50 value
of –4.95 [119]. These results indicate that the naturally occurring (8S)-isomer of gymnasterkoreayne
F is more cytotoxic than its synthetic (8R)-isomer, and these results therefore follow the tendency
observed for the cytotoxicity of Panax polyacetylenes that the stereochemistry of chiral centers may
be important for the cytotoxicity of C17 acetylenic oxylipins. Furthermore, it has been demonstrated
that gymnasterkoreayne B (82) has chemopreventive properties and hepaprotective effects through
induction of phase II detoxification enzymes NQO-1, HO-1, and glutathione reductase, as shown in
mouse and human liver cells (HepG2) [120]. The cancer chemopreventive effects of 82 have also been
investigated in HCT-116 human CRC cells and it was found that 82 significantly increases expression
levels of Nrf2 and thus induces Nrf2 to activate phase II enzymes such as NQO-1 through the regulation
of ERK and PKC pathways [121]. A structure-activity relationship study on the cancer chemopreventive
effect of gymnasterkoreayne G (84) and synthetic diyne triol derivatives revealed that the diyne moiety
is essential for the activity of these compounds [122], in accordance with the reactivity of the diyne
moiety towards biological nucleophiles (Figure 1). Furthermore, this study also showed that the chain
length has a strong effect on the chemopreventive activity of these compounds. Long chain lengths
induced better NQO-1 activity, whereas, in terms of cytotoxicity, polyacetylenes with medium-sized
or bulkier side chains exhibited better profiles [122]. However, most of the synthetic derivatives of
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gymnasterkoreayne G investigated in this study had chain length less than 17 carbon atoms and are
therefore not included in this review but a full description of their chemopreventive activity can be
found in reference [122].
Phytochemical investigations of Cirsium japonicum DC have resulted in the
isolation of several cytotoxic dehydrofalcarinol-type polyacetylenes that includes
9,10-epoxy-heptadeca-16-en-4,6-diyn-8-ol (88), heptadeca-1-en,-l,13,-diyn-8,9,10-trio1 (89), and ciryneol
A–C (90–92), which all inhibited the growth of KB cells (subline of HeLa cells) with IC50 values from
8.6 to 39.5 µg/mL [123,124].
From species belonging to the genus Artemisia several aromatic cytotoxic polyacetylenes have
been isolated [3,8]; however, C17 polyacetylenes of the dehydrofalcarindiol-type are also common in
this genus. From Artemisia monosperma Del. (3R,8R)-dehydrofalcarindiol (74) has been isolated and its
cytotoxicity evaluated against a panel of colon cancer cell lines (LS174T, SKCO-1, COLO-320DM, WIDR)
and breast cancer cell lines (MDA-231, MCF-7) with IC50 values of 9.6–14.8 µg/mL for colon cancer
cells and IC50 values of 5.8 µg/mL and 37.6 µg/mL for MCF-7 and MDA-231 cells, respectively [125].
2.3. Cytotoxic C17 and C18 Acetylenic Oxylipins Isolated from Plants of the Apiaceae
2.3.1. Cytotoxic C17 and C18 Acetylenic Oxylipins from Apicaceae Food Plants
Epidemiological studies have shown that vegetables may have cancer-preventive effects, including
those found among Apiaceae food plants such as carrot, celery, celeriac, fennel, parsley, and parsnip,
where cytotoxic acetylenic oxylipins of the falcarinol-type are common and thus may contribute to
the potential cancer-preventive effects of these vegetables [7,9]. One of the most important apiaceous
vegetables are carrots (Daucus carota L.), for two main reasons. First, they are consumed worldwide,
in particular in North America and in European countries, and second, several meta-analysis studies
on carrot consumption have indicated that carrots play a central role as a protecting vegetable, against
development of different types of cancers [126–129]. The latter has recently been confirmed in a
prospective cohort study, examining the risk of being diagnosed with CRC, as predicted by intake of
carrots in a Danish population of 57,053 individuals with a long follow-up [130]. Self-reported intake
of raw carrots at a baseline of 2–4 carrots or more each week (> 32 g/day) was associated with a 17%
decrease in risk of CRC with a mean follow-up of > 18 years, compared to individuals with no intake
of raw carrots [130]. The results of this prospective cohort study clearly support the results of the
antineoplastic effects observed for the major polyacetylenic constituents in carrots in a rat model of
CRC, as discussed in Section 4.1.
Carrots have been intensively investigated for their content of polyacetylenes and, so far,
approximately 16 different C17 acetylenic oxylipins have been isolated from carrots of which the
majority are of the falcarinol-type [7,9,131]. However, it is primarily the major polyacetylenes in carrots
that have been investigated for their cytotoxic activity, i.e., (3R)-falcarinol (1), (3R,8S)-falcarindiol (5),
and falcarindiol 3-acetate (8) [132–137]. The first study on the antiproliferative effects of falcarinol
isolated from carrots appeared in 2003 and demonstrated that this acetylenic oxylipin stimulated
differentiation of primary mammalian cells in low concentrations between 0.004 and 0.4 µM falcarinol,
whereas cytotoxic effects were found above > 4 µM falcarinol [132]. This biphasic effect on cell
proliferation is known as hormesis and is a characteristic feature of bioactive/toxic compounds [138,139],
and has been demonstrated not only for falcarinol but also for falcarindiol and falcarindiol 3-acetate in
different cell types of normal and cancer origin [134–137]. In human epithelial colorectal adenocarcinoma
(Caco-2) cells, it has been shown that cell proliferation increased at relatively low concentrations of
falcarinol (between 0.5–10 µM) where the expression of the apoptosis indicator caspase-3 decreased
concomitantly with decreased basal DNA strand breakage. At concentrations above 20 µM falcarinol,
proliferation of Caco-2 cells decreased and the number of cells expressing active caspase-3 increased
simultaneously. Furthermore, DNA single-strand breakage was significantly increased at concentrations
> 10 µM falcarinol [134]. Thus, the effects of falcarinol on proliferation of Caco-2 cells appears to be
Molecules 2020, 25, 2568 19 of 42
biphasic, inducing proproliferative and apoptotic characteristics at low and high concentrations of
falcarinol, respectively. A biphasic effect on Caco-2 cell proliferation of falcarinol and falcarindiol has
also been demonstrated in another study in concentrations ranging from 1 ng/mL to 20 µg/mL [136].
The same biphasic effects on cell proliferation have also been observed for falcarinol and falcarindiol in
myotube cultures [135] and for falcarindiol 3-acetate in different leukemia cell lines [137]. Although
a biphasic effect is a hallmark for many bioactive compounds, it is not possible based on the above
investigations to conclude, whether the proproliferative effects observed at low concentrations of
falcarinol-type polyacetylenes eventually will result in apoptosis or induce other cell responses that
later may result in cell death.
From a number of in vitro studies, it appears that falcarinol (1) is usually more cytotoxic
than falcarindiol (5) but that their cytotoxic potency against cancer cells depends on the cell
lines [9,133,136,137,140,141]. Furthermore, it appears that falcarinol and falcarindiol may have a
synergistic inhibitory effect on cell proliferation. In a study by Purup et al. [136], it was demonstrated
that the cytotoxicity of lipophilic extracts from different carrot cultivars depended on the amounts
of falcarinol, falcarindiol, and falcarindiol 3-acetate in the extracts. Extracts containing the highest
concentration of falcarinol tended to have the highest growth inhibitory effect on Caco-2 cells,
in accordance with a higher cytotoxic potency of falcarinol compared to falcarindiol. Moreover,
it was shown that the cytotoxic effect on Caco-2 cells of falcarinol was enhanced synergistically when
combined with falcarindiol in ratios of 1:1, 1:5 or 1:10 (Table 1). In addition, oxidation of the hydroxyl
group at C-3 in falcarinol to falcarinone (4) resulted in a significantly less growth inhibitory effect in
intestinal cells of both normal and cancer origin compared to falcarinol [136]. These results indicate that
the cytotoxicity of some C17 and C18 acetylenic oxylipins may be enhanced when combined and that a
hydroxyl group at C-3 may be important for their activity. The latter has also led to the proposition of
an alternative alkylation reaction mechanism of falcarinol-type polyacetylenes involving the formation
of a reactive resonance stabilized carbocation by the loss of water [136].
Table 1. Effects of different ratios of falcarinol (1) and falcarindiol (5) on the proliferation of Caco-2
cells in culture medium containing 0.625% fetal calf serum [136] a.
Falcarindiol
(µg/mL)
Falcarinol (µg/mL)
0 1 5 10
0 1.0 1.01 ± 0.25 0.36 ± 0.25 0.18 ± 0.01
1 1.35 ± 0.36 0.71 ± 0.08 b 0.58 ± 0.04 0.22 ± 0.08
5 1.03 ± 0.32 0.53 ± 0.06 b nd c nd
10 0.52 ± 0.17 0.17 ± 0.03 b nd nd
a Mean ± standard deviation is shown for each combination of falcarinol and falcarindiol. Data are presented
relative to cell proliferation obtained in medium without polyacetylenes for two individual experiments.
b Significant synergistic inhibitory effect on cell proliferation compared to single-compound assay (P < 0.01).
c nd = Not determined.
Moreover, falcarindiol and falcarindiol 3-acetate isolated from carrots have also shown to induce
apoptosis in different leukemia cell lines (CCRF-CEM, Jurkat and MOLT-3) in concentrations from
18–68 µM and 23–38 µM, respectively, whereas falcarinol only caused induction of apoptosis in one of
the cell lines (CCRF-CEM) at 45 µM [137]. On the other hand falcarinol was most cytotoxic towards
the leukemia cells with IC50 values of 12–35 µM [137]. Falcarinol and falcarindiol have also shown
in other studies that they can lead to cell cycle arrest and apoptosis of cancer cells, which may be
linked to their alkylating properties as described in the introduction [94,142–144]. For example, it has
been demonstrated that falcarindiol is able to induce ER stress in breast cancer cells (MDA-MB-231,
MDA-MB-468 and SKBR3) leading to caspase-dependent cell death (apoptosis). In addition, falcarindiol
contributed to autophagy-dependent cell death in these breast cancer cells and had synergistic effect
with approved cancer drugs 5-fluorouracil and bortezomib in killing breast cancer cells [143]. Finally,
it has been shown that falcarindiol may inhibit the growth of cancer stem cells by suppressing the Notch
Molecules 2020, 25, 2568 20 of 42
pathway, as demonstrated in neural stem cells [144]. The Notch pathway is vital to tumorigenicity of
cancer stem cells, which are the driving force of tumor development [145].
A synergistic effect between polyacetylenes isolated from carrots may be important in order to
explain the cancer-preventive effects of vegetables containing these compounds, but also indicates that
they may have a slight different mechanism of action for their cytotoxic effects. This is in accordance
with the different anti-inflammatory effects observed for falcarinol and falcarindiol (See Section 3) and
from a recent study in a rat model of CRC, where it appears that their anti-inflammatory activity is
enhanced in combination, acting as selective COX-2 inhibitors as described in Section 4.1. Furthermore,
in vitro studies have shown that falcarinol and falcarindiol have different PPARγ activity; hence, not
only do their alkylating properties appear to be important for their cytotoxic and anti-inflammatory
activity but their ability to activate nuclear receptors such as PPARγ does also, which will be discussed
in more details in Sections 3 and 4. In addition, it has been shown that the dietary polyacetylenes
falcarinol, falcarindiol, falcarindiol 3-acetate, and falcaridiol 3,8-diacetate (9) are inhibitors of the
efflux protein ABCG2 [17]. ABCG2 is an efflux transporter that is expressed both in normal and
in tumor cells and is important for xenobiotic absorption and disposition, and may play a role in
multidrug resistance in cancer, although this has not been fully established [146]. The above-mentioned
dietary falcarinol-type polyacetylenes inhibited the efflux of the ABCG2 substrate mitoxantrone
in ABCG2-overexpressed human embryonic kidney 293 cells (HEK-293). This inhibitory effect of
ABCG2 was furthermore confirmed in the vesicular transport assay, in which concentration-dependent
inhibition of the uptake of the ABCG2 substrate methotrexate into ABCG2-overexpressed Sf9 membrane
vesicles was observed with IC50 values of 19.7–41.7 µM [17]. Thus, the inhibition of ABCG2 by dietary
falcarinol-type polyacetylenes may indicate a prospective use of these polyacetylenes as multidrug
resistance reversal agents and thus a role in chemotherapy treatments.
From celery (Apium graveolens), the four polyacetylenes falcarinol, falcarindiol,
8-O-methylfalcarindiol (6) and (3R,10S)-panaxydiol (57) were isolated and tested for their cytotoxicity
against an acute lymphoblastic leukemia cell line (CEM-C7H2), a human histiocytic lymphoma cell
line (U937), a human multiple myeloma cell line (RPMI-8226), and the CRC cell lines HRT-18 and
HT-2912 [133]. Falcarinol proved to be the most active of these polyacetylenes with a pronounced
toxicity against CEM-C7H2, with an IC50 of 3.5 µM, whereas the IC50 values of falcarinol towards
the other cell lines were between 29.2–31.8 µM. This study confirms that falcarinol is one of the most
cytotoxic polyacetylenes in apiaceous vegetables.
The roots of cow parsley (Anthriscus sylvestris) have been used in Korean folk medicine as an
antitussive and diuretic, whereas the leaves are eaten raw, cooked as a potherb or used as a flavoring.
A bioassay-guided fractionation of a root extract of the plant using human colon (Colo 205) and
human leukemia (K562) cancer cells led to the isolation of several cytotoxic compounds, of which
falcarindiol was one of the most cytotoxic with IC50 values of 0.819 µg/mL (Colo 205) and 0.577 µg/mL
(K562) [147]. Falcarindiol has also been isolated from the fruits by a bioassay-guided fractionation
approach using MK-1 cells, and the antiproliferative activity of falcarindiol was tested against MK-1,
HeLa and murine melanoma (B16F10) cells and gave the following ED50 values 2.8, 55.3 and 18.3 µg/mL,
respectively [148]. Falcarindiol is also present in the edible leaves of the plant.
Falcarindiol has also been isolated as a cytotoxic constituent from Crithmum maritimum L.,
commonly known as sea fennel or rock samphire and Peucedanum japonicum also known as coastal hog
fennel [149,150]. The former has been used in folk medicine for the treatment diuretic, antiscorbutic,
digestive, and purgative properties and is consumed as a condiment. Falcarindiol isolated from
C. maritimum was tested for its cytotoxicity against normal small intestinal epithelial cells (IEC-6)
with an IC50 value of 20 µM [149]. The leaves of Peucedanum japonicum is used in Korean cuisine
as a vegetable in various dishes and in Japan it is used as a health food with medicinal properties.
The roots of P. japonicum is, however, mainly used for medicinal purposes and it has been demonstrated
that falcarindiol isolated from the roots inhibit the growth of human leukemia Jurkat T and human
promyelocytic leukemia HL-60 cells with an IC50 value of 7 µg/mL. In addition, it was demonstrated
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that falcarindiol inhibited mammalian DNA topoisomerase I at a concentration above 30 µg/mL [150].
DNA topoisomerase is an essential enzyme that control the changes in DNA structure and an inhibition
of this enzyme may eventually lead to apoptosis and cell death. Some natural topoisomerase I inhibitors
such as the alkaloid camptothecin are used in cancer chemotherapy.
Finally, a cytotoxic panaxydiol-type polyacetylene named cadiyenol (66) has been isolated from
the aerial parts of Indian pennywort (Centella asiatica (L.) Urban), which is used as a culinary vegetable
and as a medicinal herb. This compound induced apoptosis (63%) independent of cell cycle regime in
mouse lymphoma cells (P388D1) at 28 µM (IC50 = 24 µM) within 24 h [151].
2.3.2. Cytotoxic C17 and C18 Acetylenic Oxylipins from Apiaceae Medicinal Plants
Many plants belonging to the Apiaceae have a long tradition of use in traditional medicine,
even though some species are extremely toxic, such as Bupleurum longiradiatum Turcz., spotted
water-hemlock (Cicuta maculata L.), water-hemlock (C. virosa L.), and hemlock water-dropwort
(Oenanthe crocata L.) [9,152]. The former is even not allowed to be used in herbal medicine due to its
toxicity. Characteristic for toxic plant members of especially the genera Bupleurum, Cicuta and Oenanthe
are the presence of highly neurotoxic C17 and C18 acetylenic oxylipins, of which some have also been
shown to be cytotoxic.
From a dichloromethane extract of the whole plant B. longiradiatum 14 structural related acetylenic
oxylipins were isolated and tested for their cytotoxicity against the human leukemia cell line HL-60 but
only bupleurotoxin (102) and its acetate derivative (103) [Figure 5] were found to be cytotoxic, with
IC50 values of 9.4 and 4.9 µM, respectively [153]. The remaining acetylenic oxylipins isolated had IC50
values > 10 µM and were considered to be more or less inactive [153] and are therefore not discussed
further here. Bupleurotoxin is closely related to oenanthotoxin (94) that occurs in Oenanthe species
such as O. crocata [154]. Oenanthotoxin has been tested for its cytotoxicity against six different human
cancer cell lines but did only show significant cytotoxicity against an ovarian adenocarcinoma (A2780)
cell line with an EC50 (half maximal effective concentration) value of 3.8 µM, and moderate cytotoxicity
against thyroid carcinoma (8505C) and alveolar basal epithelial adenocarcinoma (A549) cell lines with
EC50 values around 10 µM [155]. In the same study, synthetic analogues of oenanthotoxin did not
result in any improvement of the cytotoxicity compared to oenanthotoxin, and therefore the results are
not included. However, a full description of their activity can be found in [155]. Based on the above
studies, it appears that the toxic polyacetylenes from Bupleurum and Oenanthe species are not obvious
sources for interesting new cytotoxic acetylenic oxylipins.
The roots and leaves of Circuta maculata have been used as an herbal remedy for the treatment of
scirrhous mammary cancer and scirrhous tumors [156]. Bioassay-guided fractionation of the active
methanol extract of the whole plant using human nasopharyngeal epidermoid carcinoma (KB) cells for
the determination of in vitro cytotoxicity resulted in the isolation of cicutoxin (93) with an ED50 value
of 2 µg/mL corresponding to 7.75 µM. Cicutoxin is also a major polyacetylene constituent in the related
species C. virosa [157]. Testing of various synthetic analogues of cicutoxin (acetates, a monobenzoate,
a benzyloxymethyl ether and a keto alcohol) for cytotoxicity resulted in significant less cytotoxicity
compared to cicutoxin with ED50 (KB) values > 4 µg/mL [156]. Based on these results, it can be
concluded that the structural requirements for cytotoxicity of cicutoxin is the presence of the conjugated
double and triple bonds as well as the two hydroxyl groups [156]. This conclusion fits well with the
conclusion of the structure-activity analysis on the closely related oenanthotoxin and its synthetic
analogues. Finally, the antileukemic effect of cicutoxin was also demonstrated in mice [156].
More than 60 species of the genus Angelica are medicinal plants and many of these have long been
used in ancient traditional medicine, especially in the Far East, such as Angelica furcijuga, A. japonica,
A. koreana, and A. sinensis, which have been used as remedy against inflammations and viral and
bacterial infections. Angelica sinensis (Oliv.) Diels is also often used in traditional Chinese medicine
for cancer treatment [158]. A bioassay-guided fractionation of the methanol extract of the roots of
A. sinensis using a MTT-assay against the murine leukemia (L1210) and human leukemia (K562) cell
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lines resulted in the isolation of several cytotoxic constituents, including the acetylenic oxylipins
falcarindiol (5) and the related C18 acetate (99). Both compounds were found to be cytotoxic against
L1210 cells with ED50 values of 2.87 µM for 5 and 2.60 µM for 99, whereas they were inactive towards
K562 cells showing ED50 values above 10 µM [159]. Falcarindiol has also been isolated as a cytotoxic
constituent of a chloroform extract of the roots of A. japonica A. Gray that showed high inhibitory activity
against human gastric adenocarcinoma (MK-1) cell growth [160,161]. Falcarindiol was isolated from
the extract by a bioassay-guided approach together with four furanocoumarin ethers of falcarindiol
(12–15), falcarinol (1), falcarindiol 8-acetate (7) and (9Z)-heptadeca-1,9-dien-4,6-diyn-3,8,11-triol (16).
The cytotoxicity of the isolated polyacetylenes against MK-1 cells showed that the cytotoxicity of
the bulky furanocoumarins of falcarindiol 12–15 with ED50 values of 5.0–16.2 µg/mL were lower
compared to falcarinol (ED50 = 0.3 µg/mL), falcarindiol (ED50 = 3.9 µg/mL), and falcarindiol 8-acetate
(ED50 = 3.2 µg/mL), and (9Z)-heptadeca-1,9-dien-4,6-diyn-3,8,11-triol (ED50 = 2.2 µg/mL) [160]. In the
same study, the antiproliferative effects of the isolated polyacetylenes were also tested against HeLa
and B16F10 cells but were found to be relatively inactive with ED50 values > 15 µg/mL for most of
the isolated polyacetylenes. For falcarindiol, these test results are in accordance with those obtained
for falcarindiol isolated from Anthriscus sylvestris described in Section 2.3.1. Other medicinal plants
belonging to Apiaceae, where falcarindiol and/or falcarinol have been isolated as the main cytotoxic
constituents are Chaerophyllum hirsutum L. [162], Cnidium officinale Makino [163], Glehnia littoralis F.
Schmidt ex Miq. [140,141,164], Heracleum moellendorffii Hance [165], and Saposhnikovae divaricata (Turcz.)
Schischk. [142,166]. For example in C. officinale falcarindiol was found to have antiproliferative effects
against MCF-7 human breast cancer cells by induction of a G0/G1 cell cycle arrest of the cells, with
an IC50 value of 35.67 µM. In addition, falcarindiol induced apoptosis through strongly increased
mRNA expression of Bax and p53, and slightly reduced Bcl-2 mRNA levels in a dose-dependent
manner [163]. These results are in accordance with a study of the cytotoxicity of an ethanol extract
of the roots/rhizomes of C. officinale. The extract was shown to inhibit the proliferation of human
colon cancer cells (HT-29) in a dose- and time-dependent manner. The mechanism of action for this
antiproliferative effect was demonstrated to be via G1 phase arrest leading to apoptosis by increasing
the expression of p53, p21, Bax and caspase-3, as well as down regulation of the antiapoptotic factor
Bcl-2 [167]. The results indicate that C. officinale root extract possesses anticancer properties and that
falcarindiol is the cytotoxic agent that can explain its cytotoxic activity.
Notopterygium incisum Ting ex H. T. Chang is a traditional Chinese herb used for the treatment of
inflammation-related diseases, and extracts of the roots and rhizomes of the plant have been shown
to exhibit potent cytotoxicity [168]. Phytochemical investigations of the underground of this plant
have led to the isolation of a large number of C17 and C18 acetylenic oxylipins [25,168]. Fourteen of
these acetylenic oxylipins have been evaluated for their cytotoxicity (1, 4, 5, 7–9, 19, 55, 57, 58, 62,
95, 97, 104), including a synthetic (3S)-isomer of notopolyenol A (56), against the cancer cell lines,
MCF-7, non-small-cell lung cancer cell line H1299, and HepG2, using the sulforhodamine B assay
and taxol as a positive control [168]. The IC50 values of the tested polyacetylenes are presented in
Table 2. Although most of the tested polyacetylenes did not show significant cytotoxicity against the
tested cell lines, it is interesting to note that the synthetic enantiomer of notopolyenol A (56) showed
high cytotoxicity from 0.6 µM to 1.6 µM in a dose around 24-fold lower than that of the naturally
occurring (3R)-isomer (55). The latter clearly indicate the importance of (3S)-configuration for the
cytotoxic effect, which is in accordance with the results from the structure-activity analysis for the
cytotoxicity of C17 polyacetylenes isolated from P. quinquefolius and their synthetic enantiomers as
described in Section 2.1.1. In addition, the panaxydiol-type polyacetylenes (57, 58, 62), with IC50 values
of 7.3–24.9 µM, displayed stronger inhibitory effects on the cancer cells than those of most of the related
falcarinol-type polyacetylenes (1, 4, 5, 7–9, 19) and their reduction products (95 and 104) [Table 2]. This
suggests that the conjugated system enlarged by the 8E-double bond may play a positive role the
cytotoxicity of panaxydiol-type polyacetylenes [168].
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Table 2. Cytotoxic effects of acetylenic oxylipins (1, 4, 5, 7–9, 19, 55, 57, 58, 62, 95, 97, 104) isolated from
Notopterygium incisum as well as the synthetic (3S)-isomer of notopolyenol A (56) and the positive
control taxol against the cancer cell lines MCF-7, H1299 and HepG2 [168].
Acetylenic Oxylipin IC50 (µM)
MCF-7 H1299 HepG2
1 43.1 ± 0.1 a 30.8 ± 0.1 45.2 ± 0.2
4 > 100 > 100 > 100
5 29.4 ± 1.0 22.1 ± 0.9 23.6 ± 2.0
7 19.0 ± 0.9 16.4 ± 0.7 15.9 ± 0.7
8 29.6 ± 1.9 21.3 ± 1.9 11.7 ± 1.2
9 67.8 ± 2.3 37.6 ± 1.3 22.7 ± 0.2
19 45.6 ± 1.5 14.6 ± 0.8 20.8 ± 1.2
55 31.7 ± 1.3 24.9 ± 0.9 35.3 ± 0.5
56 1.3 ± 0.6 0.6 ± 0.2 1.4 ± 0.7
57 13.5 ± 1.9 12.8 ± 0.9 24.9 ± 0.6
58 7.3 ± 0.4 10.7 ± 0.8 19.2 ± 2.2
62 15.1 ± 1.9 12.1 ± 0.9 23.6 ± 2.0
95 85.7 ± 0.4 31.9 ± 0.2 54.2 ± 1.6
97 > 100 > 100 29.7 ± 2.7
104 66.7 ± 1.2 36.0 ± 1.6 47.6 ± 1.9
Taxol 0.0022 ± 0.0003 0.0018 ± 0.0008 0.0020 ± 0.0007
a Mean ± standard deviation.
The roots of Seseli mairei Wolff, is used in traditional Chinese medicine for the treatment of
inflammation, swelling, rheumatism, pain, and the common cold. From an ethanol extract of the roots
of this plant showing significant cytotoxicity (ED50 < 20 µg/mL) against KB and murine lymphocytic
leukemia (P388 and L1210) tumor cells, a cytotoxic panaxydiol-type polyacetylene seselidiol (63) was
isolated by bioassay-guided fractionation [169]. The isolated seselidiol was tested against, KB, P388,
L1210 and human colon carcinoma (HCT-8) cells and showed significant cytotoxic effects with the
following ED50 values 1.0, 4.9, 3.0 and 10 µg/mL, respectively. The anticancer drug etoposide was used
as a positive control (ED50 values of 0.1–2.6 µg/mL). Acetylation of seselidiol to seselidiol 3,10-diacetate
(64) did not affect the cytotoxicity significantly showing ED50 values ranging from 4.0 to 7.8 µg/mL,
whereas oxidation to 3,10-dioxo-seselidiol (65) reduced the cytotoxicity significantly for all tested cell
lines, except HCT-8, showing ED50 values > 10 µg/mL [169]. Complete saturation of seselidiol resulted
as expected in an inactive compound. The results clearly indicate that the unsaturated bonds, i.e.,
terminal double bond and the diyn-ene chromophore is important for the cytotoxicity of seselidiol.
Furthermore, the secondary hydroxyl groups also seems to play a role in the cytotoxicity of seselidiol.
The results are in accordance with the structure-activity relationship studies of acetylenic oxylipins
discussed in previous sections of this review.
2.4. Cytotoxic C17 and C18 Acetylenic Oxylipins from Other Plant Families
Although polyacetylenes are only widely distributed in the plant families discussed in the previous
sections, a few cytotoxic C17 and C18 acetylenic oxylipins have been isolated from plants of other
terrestrial plant families of which some are related to those occurring in Apiaceae and Araliaceae.
The importance of unsaturated double bonds and, in particular, a terminal double bond for the
cytotoxicity of C17 acetylenic oxylipins, as described in previous sections, was confirmed in a study on
polyacetylenes isolated from the roots of Swietenia macrophylla King (Meliaceae), commonly known as
mahogany. The investigation of potential cytotoxic compounds from the roots of this plant led to the
isolation of several panaxydiol-type polyacetylenes that did not possess any terminal double bond [170].
All compounds isolated were tested for their cytotoxicity against the human hepatocellular carcinoma
cell line BEL-7402, human leukemia cell line K562, and human gastric carcinoma cell line SGC-7901.
Only the panaxydiol-type polyacetylenes 70 and 71 showed moderate cytotoxicity against the above
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three human cancer cell lines, with IC50 values ranging from 14.3 to 45.4 µM, whereas the other
panaxydiol-type polyacetylenes (chemical structures not shown) were inactive (IC50 > 50 µM) [170].
From Toona ciliata var. ciliate M. Roem., another plant species belonging to Meliaceae the cytotoxic
panaxydiol-type polyacetylene 69 was isolated from an ethyl acetate extract of the leaves and tested for
in vitro inhibitory activities against HL-60, SMMC-7721, A549, SK-BR-3, and PANC-1 human tumor
cell lines. However, significant cytotoxicity was only observed against the HL-60 cells with an IC50
value of 6.7 µM. Two other related C18 acetylenic oxylipins that were also isolated from the plant were
inactive [171].
The stems and leaves of Scurrula atropurpurea (Blume) Danser (Loranthaceae), a parasitic plant
that attacks the tea plant Thea sinensis (Theaceae), have been traditionally used for the treatment
of cancer in Java (Indonesia) [172]. Three C18 acetylenic oxylipins octadeca-8,10-diynoic acid (107),
(Z)-octadec-12-en-8,10-diynoic acid (108), and octadeca-8,10,12-triynoic acid (109) (Figure 6) were
isolated from 70% aqueous acetone extracts of stems and leaves. All compounds showed inhibitory
activity against cancer cell invasion (MM1 cells) in vitro in a concentration of 10 µg/mL and 109 even
down to 5 µg/mL with 95% inhibitory activity [8,173].
Figure 6. Cytotoxic C18 polyacetylenic acid isolated from Mitrephora glabra (Annonaceae) (105, 106),
Scurrula atropurpurea (Loranthaceae) (107–109) and plants belonging to the Oleaceae family (110–112).
Another polyacetylenic C18 acid that has shown interesting cytotoxic activities is minquartynoic
acid (111) (Figure 6), which was initially isolated from the stem bark of Minquartia guianensis
Aubl. (Oleaceae), also known as Black Manwood or Huambula, by bioassay-guided fractionation
using the lymphocytic leukemia cell line P388. Minquartynoic acid was found to inhibit P388
cells with an ED50 value of 0.18 µg/mL [174]. Later, minquartynoic acid was isolated from the
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air-dried bark of Coula edulis Baill., also known as African walnut (Oleaceae) [175], and the twigs of
Ochanostachys amentacea (Olacaceae) [176,177]. The twigs of O. amentacea was also found to contain
two other cytotoxic minquartynoic acid derivatives, (E)-15,16-dihydrominquartynoic acid (110) and
18-hydroxyminquartynoic acid (112) (Figure 6). All three compounds were tested against a panel
of 10 human tumor cell lines (BC1, Lu1, Col2, KB, KB-V+, KB-V-, LNCaP, SW626, SKNSH, M109)
and found to be significantly cytotoxic with ED50 values ranging from 0.3 to > 20 µg/mL (110), 1.4 to
5.5 µg/mL (111), and 2.6 to > 20 µg/mL (112) [176]. However, 110 exhibited the most potent activity
among the three polyacetylenes against the KB, LNCaP (prostate cancer), and SW626 (ovarian cancer)
cell lines [176]. Based on the test results it appears that a terminal methyl group at C-18 augment
cytotoxic activity of these C18 polyacetylenic acids.
Finally, the two cytotoxic C18 polyacetylenic acids, octadeca-9,11,13-triynoic acid (105) and
octadeca-17-en-9,11,13-triynoic acid (106) (Figure 6) were isolated from an organic fraction of a defatted
aqueous methanol extract of the stem bark of Mitrephora glabra Scheff. (Annonaceae) by bioassay-guided
fractionation using a human oral epidermoid carcinoma KB bioassay [178]. The C18 polyacetylenic
acids 105 and 106 were tested against a panel of cancer cell lines including KB, MCF-7, NCI-H460
(human large cell lung carcinoma) and SF-268 (human astrocytoma) cells with IC50 values ranging
from 10 to 40 µM. The methyl ester of 105 was also isolated and tested but was completely inactive
suggesting that the methyl ester diminishes cytotoxicity [178].
2.5. Moieties and Stereochemistry that Are Important for the Cytotoxicity of C17 and C18 Acetylenic Oxylipins
The cytotoxicity of C17 and C18 acetylenic oxylipins depends on many factors such as their
reactivity towards biological nucleophiles, receptor/ligand binding affinity as well as their rate of
metabolization. Based on structure–activity analysis studies on the cytotoxic effects of C17 and C18
acetylenic oxylipins discussed in Sections 2.1–2.4, it appears that the diyne functionality is essential for
their cytotoxic effects, which is also an important requirement for their reactivity towards biological
nucleophiles such as amino acids in proteins (Figure 1). Larger acetylenic chromophores such as triynes
and tetraynes contribute to the electrophilic nature of C17 and C18 acetylenic oxylipins, which may
explain their cytotoxic activity. In addition, the configuration of asymmetric centers is important for the
cytotoxicity of C17 and C18 acetylenic oxylipins and in particular, the asymmetric center at C-3 where
(3S)-configurated acetylenic oxylipins appears to be more cytotoxic than the (3R)-isomers. Synthetic
compounds containing a 1,3-butadiynylcarbinol motifs have been identified as leads for cytotoxicity
against cancer cell lines such as HCT116, HepG2 and Hela cancer cells, and these studies also confirm
the importance of the configuration of the chiral center of the secondary alcohol group, where the
(S)-isomers are generally more cytotoxic than the corresponding (R)-isomers [179,180]. The latter is also
in accordance with another study on the cytotoxicity of synthetic chiral acetylenic lipids against various
cancer cell lines [181]. However, the configuration at C-3 in most C17 and C18 oxylipins is not critical for
their activity because polyacetylenes with R-configuration also exert significant cytotoxicity. A terminal
double bond in position 1,2 appear, however, to be critical for their cytotoxicity as reduction of the
terminal double bond to the corresponding dihydro-derivatives reduces their cytotoxicity significantly.
Acetylation and oxidation of the secondary allylic alcohol also diminishes their cytotoxicity and a
terminal allylic secondary alcohol is therefore considered important but not critical for the cytotoxicity
of C17 and C18 acetylenic oxylipins. Oxidation of the double bond at C-9 and C-10 in, for example,
falcarinol-type polyacetylenes to an epoxide or dihydroxy-derivative is not important for activity,
although epoxides are known to be reactive towards nucleophiles. A rearrangement of the 9Z-double
bond in falcarinol-type polyacetylenes to an 8E-double bond as in panaxydiol-type polyacetylenes
appears to enhance the cytotoxicity, although further studies are needed in order to conclude on the
importance of the rearrangement from a 9Z to an 8E-double bond for the cytotoxicity of C17 and C18
acetylenic oxylipins. Finally, the length of the aliphatic carbon chain appears to be important because
C17 acetylenic oxylipins seem to be more active than the corresponding C18 analogues (see Section 2.1.2)
and furthermore, it has been shown that the cytotoxicity drops off dramatically in both natural and
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synthetic polyacetylenes as the chain length shortens, as described in Section 2.1.1. The moieties,
stereochemistry, and other structural requirements that are important for the cytotoxicity of C17 and C18
acetylenic oxylipins are summarized in Figure 7; thus indicating important leads for the development
of new potential acetylenic anticancer drugs.
Figure 7. Illustration of moieties, stereochemistry and other structural requirements that are important
for the cytotoxicity of C17 and C18 acetylenic oxylipins (falcarinol as an example) isolated from Apiaceae,
Araliaceae, and Asteraceae families based on structural-activity relationship studies.
3. In Vitro Anti-Inflammatory Activity of C17 and C18 Acetylenic Oxylipins
From Section 2, it is clear that many C17 and C18 acetylenic oxylipins exhibit strong cytotoxic activity
towards various types of cancer cells and thus may have a chemopreventive effect. The mechanisms of
action for the cytotoxic activity of these acetylenic oxylipins may vary depending on the cancer type,
but one of the driving mechanisms in the development and progression of cancer is the formation of
proinflammatory cytokines and enzymes, as described in the introduction. Despite the existence of a
clear connection between cancer and chronic inflammation, it is striking that only a few investigations in
the literature have studied the anti-inflammatory effects of these highly bioactive secondary metabolites.
In addition, many of the medicinal plants belonging to the Apiaceae, Araliaceae, and Asteraceae families,
where C17 and C18 acetylenic oxylipins are common, have been used to treat inflammatory diseases,
which furthermore indicates that these compounds possess interesting anti-inflammatory activities.
As described in the introduction, the transcription factor NF-κB plays a key role for the inducible
expression of genes mediating proinflammatory effects; thus, NF-κB signaling pathway inhibitors
are not only potential anti-inflammatory but also anticancer drug candidates [182–184]. A large
variety of inflammatory stimuli leads to NF-κB activation, including carcinogens, lipopolysaccharide
(LPS), nitric oxide (NO) and proinflammatory cytokines, such as IL-6, IL-1β and TNF-α [182,183].
In a study by Metzger et al. [185], it was demonstrated that fractionation of a methanol extract of
purple carrots by solid phase chromatography on a Sephadex LH-20 column resulted in a fraction that
reduced LPS inflammatory response in macrophage and porcine aortic endothelial cells. The active
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fraction showed a dose-dependent reduction in NO production and mRNA of the proinflammatory
cytokines IL-6, IL-1β, and TNF-α as well as NO synthase (iNOS) in macrophage cells. In porcine aortic
endothelial cells treated with 6.6 and 13.3 µg/mL of the active fraction, the protein secretions of IL-6
and TNF-α were reduced by 77% and 66%, respectively. The active fraction was shown to consist of
the polyacetylenes falcarinol, falcarindiol and falcarindiol 3-acetate, which were shown in the study
to reduce NO production in macrophage cells by as much as 65% without cytotoxicity. These results
clearly demonstrate that the anti-inflammatory compounds in carrots are falcarinol-type polyacetylenes.
Falcarinol and falcarindiol isolated from a methanolic extract of the roots of Angelica furcijuga Kitagawa
was also found to inhibit NO production induced by LPS in cultured mouse peritoneal macrophages
with IC50 values of 4.8 and 4.4 µM, respectively [186,187]. In addition, falcarindiol inhibited TNF-α
with an IC50 value of 48 µM [187]. Falcarindiol has also been shown to dose-dependently (1, 5 and
10 µM) reduce the inducible iNOS-mediated NO production without cytotoxic effects on LPS-activated
BV-2 microglia cells and microglia [188], and to inhibit NO release from LPS-stimulated RAW 264.7
macrophage cells, with an IC50 value of 4.31 µM [163]. In a study of falcarindiol isolated from the stem
of Oplopanax elatus it was demonstrated that falcarindiol inhibited the formation of NO in LPS-induced
RAW 264.7 macrophage cells with an IC50 value of 1.28 µM. Other anti-inflammatory polyacetylenes
isolated from O. elatus that showed to inhibit NO formation were oploxyne A (39) and oplopandiol (18)
with IC50 values of 1.98 and 2.72 µM, respectively. All three polyacetylenes also showed inhibition of
the major PG, PGE2, in LPS-induced macrophages with IC50 values in the range of 1.54 to 3.08 µM,
which indicate that they inhibit COX enzymes [109]. For falcarindiol, this is in accordance with other
studies as described in next paragraph. In addition, the panaxydiol-type polyacetylene cadiyenol
(66) has been shown to inhibit NO production in a dose-dependent manner in mouse RAW 264.7
macrophage cells, reducing NO production by 70% at 24 µM [151].
Falcarindiol appears to be an effective inhibitor of COX-2 in vitro, as demonstrated in colon cancer
and colon epithelial cells [141,189] and in LPS-stimulated RAW 264.7 macrophage cells [163], as well
as a an effective COX-1 inhibitor [190–192], where an IC50 value of 0.3 µM has been reported [190].
Investigations on the COX inhibitory effects of other polyacetylenes are limited; however, it has been
shown that falcarinol and panaxydiol significantly inhibit the mRNA expression of COX-2 in colon
cancer cells as well as iNOS, but their activity was less compared to falcarindiol [141]. Inhibitory activity
of COX-1 has also been demonstrated for falcarinol, falcarindiol 8-acetate (7) and dehydrofalcarindiol
(73), and again the COX inhibitory activity of these polyacetylenes was considerably less compared to
falcarindiol [191,193]. In addition, falcarinol and falcarindiol have shown to be strong inhibitors of LOXs
(5-, 12- and 15-LOX), which, like COX enzymes, are involved in tumor-progression processes [193–195].
In a study by Alanko et al. [193], the IC50 values for inhibition of 5-LOX, 12-LOX of leukocyte-type
and platelet-type and 15-LOX for falcarinol were 2, 1, 67 and 4 µM, respectively. For falcarindiol the
IC50 values were 7, 48, > 100 and 18 µM, respectively, which indicates that falcarinol is a more efficient
inhibitor of LOXs than falcarindiol. Finally, falcarinol and falcarindiol have also been shown to inhibit
the formation of thromboxanes and thus have antiplatelet properties [196–198].
Investigations of the anti-inflammatory activity of C17 and C18 acetylenic oxylipins, indicates
that this bioactivity may play an important role in their anticancer effects, at least for some cancers
such as CRC where inflammation plays a central role in the development and progression of this
disease. This has recently been demonstrated for falcarinol and falcarindiol in a rat model of CRC as
described in Section 4.1. In addition, falcarinol has been shown to reduce induced acute intestinal and
systemic inflammation in a mice model by exerting anti-inflammatory activity through activation of
the Keap1-Nrf2 pathway, as described in more detail in Section 4. However, it is clear that information
about the potential anti-inflammatory effects of C17 and C18 acetylenic oxylipins is lacking in the
literature, with a few exceptions. Therefore, it is suggested that future investigations on the anticancer
effect of these bioactive acetylenic oxylipins should focus more on their direct anti-inflammatory
activity as well as the anti-inflammatory effect related to the activation of the Keap1-Nrf2 pathway.
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This is likely to give new important knowledge and insight into the mechanisms of action of the
chemopreventive effects of C17 and C18 acetylenic oxylipins.
4. In Vivo Anticancer Activity of C17 and C18 Acetylenic Oxylipins
4.1. In Vivo Studies of the Chemopreventive Effect of Falcarinol and Falcarindiol in a Rat Model for CRC
Studies on the in vivo anticancer effect of acetylenic oxylipins are few and the most detailed
in vivo studies concerns the investigation of the cancer-preventive effects of carrots and their main
polyacetylenic constituents, falcarinol and falcarindiol, in relation to the development of CRC.
As mentioned in Section 2.3.1 there is evidence from meta-analysis and cohort studies that carrots have
cancer-preventive effects against several types of cancers, including CRC. There is strong evidence for
the existence of a link between CRC development and the expression of COX enzymes, and in particular
COX-2 [37]. COX-2 overexpression but not COX-1 has been detected in 50% of colorectal adenomas
and in up to 85% of colorectal carcinomas, and it is correlated with poor prognosis, and therefore
COX-2 is considered as one of the most important drug targets for the prevention of CRC [39].
This is consistent with the fact that CRC development often is linked with chronic inflammation
resulting in a microenvironment conducive for the development of early neoplastic lesions due to
relative high concentrations of PGs [199]. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as
aspirin are known COX inhibitors, and they have been widely used for cancer prophylaxis [200].
However, several adverse effects have been associated with the long-term usage of NSAIDs such as
gastrointestinal bleeding, asthma, hepatic, renal and cardiovascular toxicity, primarily due to their
irreversible inhibition of COX enzymes and in particular COX-1; hence, their clinical application
has been limited [201]. Consequently, dietary secondary metabolites such as polyacetylenes that
are known for their cytotoxic and anti-inflammatory activities have therefore been considered as
promising chemopreventive candidates because they inherently show low toxicity and a promising
safety profile with no known severe side effects. Falcarinol has so far only shown unwanted toxic
effects when delivered in high doses upon injection (100 mg/kg) to rodents, where it causes neurotoxic
symptoms [202], whereas falcarindiol does not seem to have any toxic effect [203]. Unwanted toxic
effects of falcarinol and falcarindiol in humans by even a relatively high intake of carrots and/or
processed carrot products or other apiaceous vegetables is therefore not expected and this is the
background for the investigation of the cancer-preventive effects of these major dietary polyacetylenes
in CRC rat models [52,53,204].
So far, three preclinical trials have been performed on falcarinol and falcarindiol isolated from
carrots in azoxymethane (AOM)-induced rats, which is an accepted in vivo CRC model [52,53,204,205].
AOM is a potent carcinogen, which is an efficient inducer of aberrant-crypt foci (ACF) and other
precancerous lesions as well as CRC in rats [53,205]. Only a small number of early neoplastic ACF lesions
will develop to neoplastic polyp lesions and only a small number of these lesions will have the potential
to develop into adenomas and cancers [206,207]. All three clinical trials demonstrated chemopreventive
effects on CRC [52,53,204]. In the most recent clinical trial the dose-dependent antineoplastic effect of
purified falcarinol and falcarindiol in AOM-induced rats was investigated as well as their possible
mechanisms of action. Groups of 20 rats received a standard rat diet (SRD) supplemented with 0.16,
0.48, 1.4, 7 or 35 µg falcarinol and falcarindiol/g feed in the ratio 1:1, respectively, and 20 rats were
controls receiving only SRD [52]. The ratio 1:1 of falcarinol and falcarindiol in the rat feed was based
on the synergistic cytotoxic effects of these polyacetylenes described in Section 2.3.1.
Analysis of aberrant crypt foci (ACF) in the above study showed that the average number of small
ACF (< seven crypts) and large ACF (> seven crypts) decreased with increasing dose of falcarinol and
falcarindiol and that this inhibitory effect on early neoplastic formation was dose-dependent (Table 3).
A dose-dependent effect on the total number of macroscopic neoplasms was also observed (Table 3).
Not surprisingly, the largest antineoplastic effect was observed at the highest doses of falcarinol
and falcarindiol in the feed. Interestingly, adenomas were, in general, smaller in the falcarinol- and
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falcarindiol-treated rats, especially at the highest doses compared to the control group [52]. This clinical
trial clearly demonstrated a dose-dependent chemopreventive effect of falcarinol and falcarindiol on
the formation of neoplastic lesions in the colon of rats. In addition, the study also indicated that these
dietary polyacetylenic oxylipins might exert a growth inhibition of neoplastic lesions, as they not
only reduce the number of macroscopic polyp neoplasms but also their size. The latter suggests that
falcarinol and falcarindiol exert a cytotoxic and thus a kind of chemotherapeutic effect. The dose for
an optimal antineoplastic effect was found to be from 7 to 35 µg of falcarinol and falcarindiol/g feed
in the rat model of CRC. However, effects are observed at even lower concentrations (Table 3) and it
appears that a cancer-preventive dose of polyacetylenes in humans, based on this preclinical trial, can
be achieved with a daily intake above 30 g raw carrots [52,130], which is in accordance with the results
of the cohort study mentioned in Section 2.3.1.
Table 3. Small aberrant crypt foci (ACF) (< seven crypts) and large ACF (> seven crypts) and the total
number of macroscopic polyp neoplasms (tumors > 1 mm) in six groups of 20 azoxymethane-induced
rats receiving a standard rat diet (SRD) or a SRD supplemented with different doses of falcarinol (1)
and falcarindiol (5) (ratio 1:1). Data are shown as mean ± standard deviation [52].
Size of Neoplasms µg Falcarindiol and Falcarinol (1:1)/g Feed
0 (n = 20) 0.16 (n = 20) 0.48 (n = 20) 1.4 (n = 20) 7 (n = 20) 35 (n = 20)
Mean ACF < 7 crypts a 205 ± 36 207 ± 28 180 ± 29 171 ± 26 150 ± 31 145 ± 19
Mean ACF > 7 crypts b nd c 14 ± 3.7 12 ± 4.1 10 ± 3.7 nd 8 ± 3.5
Total number of
macroscopic polyp
neoplasms d
21 18 19 13 12 7
a Significant dose-response effect according to linear regression analysis (R2 = 0.3742, P < 0.001). b Significant
dose-response effect according to linear regression analysis (R2 = 0.2451, P < 0.001). c nd = no data are available.
d Dose-response relationship determined by Poisson regression with the number of macroscopic lesions decreasing
by 0.167 for each log-fold increase in dose (P = 0.007).
Gene expression studies performed by real-time quantitative PCR on selected cancer biomarkers
in neoplastic tissue from the rat model of CRC revealed that falcarinol and falcarindiol downregulated
NF-κβ and its downstream proinflammatory markers TNFα, IL-6, and COX-2, whereas biomarkers
such as COX-1 and IL-1β were not significantly affected [52]. Furthermore, the gene expression study
showed a downregulation of PPARγ. The downregulation of COX-2 in adenomas from rats receiving
SRD supplemented with falcarinol and falcarindiol compared to adenomas of the control group
was furthermore confirmed by immunohistochemical analysis [52]. A significant downregulation of
COX-2 in rats receiving SRD supplemented with falcarinol and falcarindiol implies the involvement
of COX-2 in CRC development and, thereby, clearly indicates that COX-2 is an important target for
the chemopreventive effects of these polyacetylenes. Based on the results of this preclinical trial,
it appears that falcarinol and falcarindiol in combination act as selective COX-2 inhibitors, which is
highly interesting in relation to the development of anti-inflammatory and anticancer drugs with no
severe side effects.
The significant downregulation of NF-κB in tumor tissue in rats receiving SRD supplemented
with falcarinol and falcarindiol compared to the control group confirms that inflammation plays a key
role in early neoplastic formation and that the chemopreventive effect of falcarinol and falcarindiol
in the colon is linked to their anti-inflammatory activity [52]. In addition, the downregulation of the
proinflammatory cytokines TNFα and IL-6 in tumor tissue in rats receiving SRD supplemented with
falcarinol and falcarindiol is further evidence for the anti-inflammatory action and chemopreventive
effects of these dietary polyacetylenes. An upregulation of TNFα is linked to increased leukocyte
infiltration and tumor formation and is usually detected in colorectal neoplasms, and in animal models
of CRC [208,209] and IL-6 is highly upregulated in many cancers and is considered as one of the most
important proinflammatory cytokines during carcinogenesis and metastasis [48].
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The nuclear receptor PPARγ controls the expression of a large number of regulatory genes in
inflammation and cell proliferation. In the colon, PPARγ plays a key role in the control of intestinal
inflammation such as ulcerative colitis [210]. Furthermore, PPARγhas been found to have antineoplastic
properties being able to induce apoptosis and differentiation of colon cancer cells both in vivo and
in vitro [211]. The regulation of PPARγ expression in the colon is unresolved but PPARγ expression
may be upregulated by intestinal-microbial interactions involving LPS of Gram-negative bacteria and/or
ligands of PPARγ [52,211]. A number of acetylenic C17 and C18 oxylipins, including falcarinol and
falcarindiol have been shown to be ligands of PPARγ and to activate this nuclear receptor [23–25,212].
This seems to explain their antidiabetic properties and may contribute to their anti-inflammatory
and anticancer activities; thus, an increased expression of PPARγ in epithelial cells would have been
expected in rats receiving falcarinol and falcarindiol in the diet. The significant downregulation of
PPARγ in rats receiving falcarinol and falcarindiol in the diet compared to the control group indicates,
however, that PPARγ may not be an important target for the antineoplastic effect in the colon of these
polyacetylenic oxylipins. This may be explained by recent research that has shown that falcarinol and
falcarindiol alter the gut microbiota composition in the AOM-induced rat model [213], resulting in a
downregulation of the expression of PPARγ in the tumor tissue observed in the above preclinical trial
instead of an expected upregulation [52].
The anti-inflammatory activities observed in the rat model for CRC may be linked to their
ability to activate the Keap1-Nrf2 pathway as recently demonstrated in CB57BL/6 mice. In this study
pretreatment of 5 mg falcarinol/kg twice a day for one week against LPS-induced acute intestinal
and systemic inflammation was shown to reduce the magnitude of intestinal proinflammatory gene
expression (IL-6, TNFα, INFγ, STAT3, and IL-10) [26]. Furthermore, falcarinol was shown to upregulate
the cytoprotective enzyme HO-1 in both the intestine and in the liver and to reduce basal lipid
peroxidation in the mesentery. Finally, falcarinol was shown to protect against LPS-induced reduction
in intestinal barrier integrity as well as reduced inflammatory cell infiltration [26]. Hence, the results
from this study to some extent support the results of the anti-inflammatory mechanisms of action for
the cancer-preventive effects of falcarinol and falcarindiol observed in the CRC rat model.
Collectively, the results of the above preclinical trial demonstrate that falcarinol and falcarindiol in
combination have a dose-dependent chemopreventive effect on neoplastic lesions in a rat model of CRC,
and that this effect is most likely due to inhibition of downstream proinflammatory markers in the NF-κB
signaling pathway. In particular, COX-2 seems to be an important target for the anti-inflammatory and
antineoplastic effect of falcarinol and falcarindiol in relation to the development of CRC.
4.2. Studies of the Anticancer Effect of C17 and C18 Acetylenic Oxylipins in Other In Vivo Models
As described in in Section 2.1.2 (3S,8S)-falcarindiol (10) and oplopantriol A (97) isolated from
Oplopanax horridus has been shown to be cytotoxic to several types of cancer cell lines. The in vivo
anticancer effects of these polyacetylenes have been evaluated in a xenograft tumor model using
the human CRC cell line HCT-116 [102,106,107]. The in vivo antitumor potential of falcarindiol was
evaluated in two studies by inoculating firefly luciferase-tagged HCT-116 cells into the flanks of athymic
nude mice [102,107]. Falcarindiol in a concentration of 15 mg/kg was administered intraperitoneally
every day starting from day 1. Quantitative analysis of imaging data revealed that falcarindiol
significantly inhibited xenograft tumor growth in week 2 (P < 0.05) and much more significant in
weeks 3 and 4 (P < 0.01) after falcarindiol administration compared to vehicle administration (control).
In addition, the cytotoxicity of falcarindiol was evaluated on the normal rat small intestine epithelial
cell line (IEC-6) but did not show any cytotoxicity even at a concentration of 20 µM, whereas, at 10 µM,
the cell growth of HCT-116 cells was almost completely inhibited [102]. Consequently, falcarindiol
showed significant antitumor activity in the HCT-116 xenograft tumor model and was relatively safe
to normal intestinal cells. The same HCT-116 xenograft tumor model has also been used to evaluate
the in vivo anticancer effect of oplopantriol A also in a concentration of 15 mg/kg, where quantitative
analysis of imaging data revealed a significant xenograft tumor growth starting from week 3 (P < 0.05)
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and being much more significant at weeks 4 and 5 (P < 0.01) [106]. The safety profile of oplopantriol A
was not evaluated in this study.
The cytotoxic polyacetylenes isolated from Dendropanax arboreus described in Section 2.1.2 have also
been investigated for their in vivo activity in a murine LOX melanoma xenograft model [112]. Tumor
cells were implanted in the peritoneal cavity of mice in order to provide maximal sensitivity for the
preliminary in vivo evaluations, and (3S)-falcarinol (3), dehydrofalcarinol (72) and dehydrofalcarindiol
(73), formulated in sesame oil, were injected intraperitoneal. All tested polyacetylenes showed modest
activity but still some potential for in vivo antitumor activity with dehydrofalcarinol having the greatest
activity in the employed LOX melanoma model showing the best effect at a concentration at 3 mg/kg.
In another study, orally administered (3R)-falcarinol (1) was shown to significantly suppress the
initiation and growth of lung cancer in mice models in concentrations of 50 mg/kg, without detectable
toxicity [214]. Furthermore, it was demonstrated that falcarinol suppressed carcinogenesis both in vitro
and in vivo by disrupting heat shock protein 90 (Hsp90) function and viability of both non-cancer
stem-like and cancer stem-like cells of non-small-cell lung cancer by inducing apoptosis without
increasing Hsp70 expression. Induction of apoptosis by falcarinol was demonstrated in cancer stem
like cells in nM concentrations [214]. Hsp90 is known to promote cancer cell survival and acquisition
of anticancer drug resistance by controlling the conformational maturation and stability of numerous
carcinogenic proteins, and overexpression of this protein has been observed in many human cancers and
is associated with poor prognosis [215–217]. Hsp70 is the most ubiquitous stress-inducible chaperone
and accumulates in the cells in response to a wide variety of insults including anticancer chemotherapy,
and is known to inhibit key effectors of the apoptotic and autophagy machineries. In tumors and
cancer cells, the expression of Hsp70 is very high, and Hsp70 may participate in carcinogenesis and in
resistance to chemotherapy [218]. The mechanism by which falcarinol disrupted the function of Hsp90
and did not overexpress Hsp70 was shown to occur by binding to the N-terminal and C-terminal ATP
binding pockets of the protein, resulting in destabilization of its client proteins, as shown both in vitro
and by molecular docking studies [214]. This in vivo and in vitro study demonstrates that falcarinol
is a potential inhibitor of Hsp90 with limited toxicities and interestingly give new insight into the
possible mechanisms of action for the anticancer effect of falcarinol and related acetylenic oxylipins.
Panaxydol (20), which has shown to induce cell cycle arrest and apoptosis in cancer, as described
in Section 2.1.1, has also been investigated for its antitumor effect in vivo in mice tumor models [76].
Syngeneic BALB/c mice were inoculated in the flank with mouse renal cell carcinoma Renca cells one
week before administration of 100 or 200 mg/kg panaxydol therapy by i.p. injection every two days for
three weeks, which resulted in a dose-dependent reduction of tumor size. Inhibition of in vivo tumor
growth was also demonstrated with a human prostate cancer (PC3) xenograft where PC3 cells were
inoculated in BALB/c nude mice one week before the initiation of three-week panaxydol therapy (50 or
100 mg/kg every 2 days). This resulted in inhibited growth of the PC3 xenograft dose-dependently,
with complete suppression at 100 mg/kg [76]. The results of these in vivo studies, in combination with
its in vitro cytotoxicity, suggest that panaxydol is a promising anticancer candidate or lead compound
for the development of efficient anticancer drugs.
Finally, in vivo antitumor efficacy of (3R,9R,10R)-panaxytriol (36) isolated from P. ginseng has
been shown to significantly delay tumor growth in C57BL/6 mice (P < 0.01) transplanted with B 16
melanomas when administered intramuscularly with panaxytriol in a concentration of 40 mg/kg [80,219].
Furthermore, the in vivo antitumor efficacy of panaxytriol has been evaluated in human breast cancer
xenograft (MX-1) mice models, where the mice where treated with panaxytriol at various dosages
through intravenous infusion [220]. Mice treated with 30 mg/kg of panaxytriol exhibited some
suppression of tumor growth, but no appreciable shrinkage in tumor mass was observed; thus no
chemotherapeutic effect. At elevated dosage levels, i.e., at 50 mg/kg, improved inhibitory effects were
observed. No changes in body weight were observed upon treatment, which clearly indicate that the
antitumor activity achieved with panaxytriol is apparently not accompanied by any toxic side effects,
even at high dosage levels.
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5. Conclusions
The present review has demonstrated that C17 and C18 acetylenic oxylipins constitute an interesting
class of cytotoxic natural products that may be used in the prevention and treatment of cancers and
as lead compounds for the development of anticancer drugs. The mechanisms of actions of these
acetylenic oxylipins are the same as for many anticancer drugs, such as inducing ER stress, cell cycle
arrest, apoptosis, and/or reduce inflammation, but, interestingly, some of the cytotoxic acetylenic C17
oxylipins that have been tested in preclinical trials and demonstrated an anticancer effect do not show
any significant toxic side effects. However, only a few cytotoxic polyacetylenes have been tested in
preclinical trials, and, so far, none of them has been tested in clinical trials, although there is evidence
for a likely cancer-preventive effect of dietary polyacetylenes from meta-analysis and cohort studies.
Polyacetylenes most often do not occur in large amounts in plants and furthermore they are unstable,
being sensitive to heat, light and oxidation [3,7], and, therefore, it is a challenge to isolate relatively
large amounts of these compounds from plants for preclinical trials. This may also be one of the
explanations for the relatively few preclinical trials performed on these compounds. Still, the present
review may encourage more preclinical trials and initiate clinical trials in particular on the dietary
polyacetylenes in order to obtain more evidence for their anticancer effect as well as to obtain more
information on their pharmacokinetics and mechanisms of action, including their potential targets
in cells.
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